WO2024023580A2 - Stabilizing rnas with mirna-binding motifs - Google Patents
Stabilizing rnas with mirna-binding motifs Download PDFInfo
- Publication number
- WO2024023580A2 WO2024023580A2 PCT/IB2023/000449 IB2023000449W WO2024023580A2 WO 2024023580 A2 WO2024023580 A2 WO 2024023580A2 IB 2023000449 W IB2023000449 W IB 2023000449W WO 2024023580 A2 WO2024023580 A2 WO 2024023580A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- mirna
- mir
- target rna
- rna molecule
- Prior art date
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title claims abstract description 179
- 108091070501 miRNA Proteins 0.000 title claims abstract description 105
- 230000000087 stabilizing effect Effects 0.000 title claims abstract description 97
- 230000027455 binding Effects 0.000 title claims description 17
- 102000040650 (ribonucleotides)n+m Human genes 0.000 title description 22
- 239000002679 microRNA Substances 0.000 claims abstract description 137
- 238000000034 method Methods 0.000 claims abstract description 77
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 34
- 210000004027 cell Anatomy 0.000 claims description 165
- 125000003729 nucleotide group Chemical group 0.000 claims description 91
- 239000002773 nucleotide Substances 0.000 claims description 90
- 210000001519 tissue Anatomy 0.000 claims description 75
- 230000000295 complement effect Effects 0.000 claims description 58
- 108020004999 messenger RNA Proteins 0.000 claims description 46
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 229920001184 polypeptide Polymers 0.000 claims description 21
- 108020004414 DNA Proteins 0.000 claims description 19
- 230000001225 therapeutic effect Effects 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 7
- 210000005229 liver cell Anatomy 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 6
- 108091056281 miR-449b stem-loop Proteins 0.000 claims description 6
- 108091059726 miR-449c stem-loop Proteins 0.000 claims description 6
- 108091062489 miR-514a-1 stem-loop Proteins 0.000 claims description 6
- 108091046053 miR-514a-2 stem-loop Proteins 0.000 claims description 6
- 108091047994 miR-514a-3 stem-loop Proteins 0.000 claims description 6
- 210000001550 testis Anatomy 0.000 claims description 6
- 210000002064 heart cell Anatomy 0.000 claims description 5
- 108091030733 miR-205 stem-loop Proteins 0.000 claims description 5
- 210000002569 neuron Anatomy 0.000 claims description 5
- 210000000952 spleen Anatomy 0.000 claims description 5
- 102000053602 DNA Human genes 0.000 claims description 4
- 206010062767 Hypophysitis Diseases 0.000 claims description 3
- 108091093142 MiR-144 Proteins 0.000 claims description 3
- 108091046841 MiR-150 Proteins 0.000 claims description 3
- 108091033773 MiR-155 Proteins 0.000 claims description 3
- 108091062140 Mir-223 Proteins 0.000 claims description 3
- 108091093189 Mir-375 Proteins 0.000 claims description 3
- 108091080995 Mir-9/mir-79 microRNA precursor family Proteins 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000002752 melanocyte Anatomy 0.000 claims description 3
- 108091056924 miR-124 stem-loop Proteins 0.000 claims description 3
- 108091077112 miR-128a stem-loop Proteins 0.000 claims description 3
- 108091024038 miR-133a stem-loop Proteins 0.000 claims description 3
- 108091047757 miR-133a-1 stem-loop Proteins 0.000 claims description 3
- 108091057540 miR-133a-2 stem-loop Proteins 0.000 claims description 3
- 108091055152 miR-133a-3 stem-loop Proteins 0.000 claims description 3
- 108091079016 miR-133b Proteins 0.000 claims description 3
- 108091043162 miR-133b stem-loop Proteins 0.000 claims description 3
- 108091058688 miR-141 stem-loop Proteins 0.000 claims description 3
- 108091062895 miR-144 stem-loop Proteins 0.000 claims description 3
- 108091086416 miR-192 stem-loop Proteins 0.000 claims description 3
- 108091059199 miR-200a stem-loop Proteins 0.000 claims description 3
- 108091063796 miR-206 stem-loop Proteins 0.000 claims description 3
- 108091037327 miR-449 stem-loop Proteins 0.000 claims description 3
- 108091040525 miR-449a stem-loop Proteins 0.000 claims description 3
- 108091023818 miR-7 stem-loop Proteins 0.000 claims description 3
- 108091047084 miR-9 stem-loop Proteins 0.000 claims description 3
- 108091007420 miR‐142 Proteins 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 230000002107 myocardial effect Effects 0.000 claims description 3
- 210000003635 pituitary gland Anatomy 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 230000014509 gene expression Effects 0.000 abstract description 43
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 241000711549 Hepacivirus C Species 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 41
- 108700011259 MicroRNAs Proteins 0.000 description 37
- 108091007780 MiR-122 Proteins 0.000 description 30
- 108091051828 miR-122 stem-loop Proteins 0.000 description 30
- 102000040430 polynucleotide Human genes 0.000 description 26
- 108091033319 polynucleotide Proteins 0.000 description 26
- 239000002157 polynucleotide Substances 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 25
- 230000001413 cellular effect Effects 0.000 description 15
- 230000003993 interaction Effects 0.000 description 15
- 101150084233 ago2 gene Proteins 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 150000007523 nucleic acids Chemical group 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 210000004962 mammalian cell Anatomy 0.000 description 11
- -1 miR181- Proteins 0.000 description 10
- 102000008682 Argonaute Proteins Human genes 0.000 description 9
- 108010088141 Argonaute Proteins Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 230000002708 enhancing effect Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 108060002716 Exonuclease Proteins 0.000 description 6
- 102000013165 exonuclease Human genes 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 5
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000012096 transfection reagent Substances 0.000 description 5
- 230000001131 transforming effect Effects 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000001163 endosome Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229940047122 interleukins Drugs 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108020003589 5' Untranslated Regions Proteins 0.000 description 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 3
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000052376 Piwi domains Human genes 0.000 description 3
- 108700038049 Piwi domains Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000025308 nuclear transport Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101000735358 Homo sapiens Poly(rC)-binding protein 2 Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102100034961 Poly(rC)-binding protein 2 Human genes 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 102000009899 alpha Karyopherins Human genes 0.000 description 2
- 108010077099 alpha Karyopherins Proteins 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108091007428 primary miRNA Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 210000003412 trans-golgi network Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000006656 viral protein synthesis Effects 0.000 description 2
- JBFQOLHAGBKPTP-NZATWWQASA-N (2s)-2-[[(2s)-4-carboxy-2-[[3-carboxy-2-[[(2s)-2,6-diaminohexanoyl]amino]propanoyl]amino]butanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)C(CC(O)=O)NC(=O)[C@@H](N)CCCCN JBFQOLHAGBKPTP-NZATWWQASA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical class [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101800002011 Amphipathic peptide Proteins 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 102000053640 Argininosuccinate synthases Human genes 0.000 description 1
- 108700024106 Argininosuccinate synthases Proteins 0.000 description 1
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 102100031939 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 108010044495 Fetal Hemoglobin Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 102100029115 Fumarylacetoacetase Human genes 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101001126085 Homo sapiens Piwi-like protein 1 Proteins 0.000 description 1
- 101000780643 Homo sapiens Protein argonaute-2 Proteins 0.000 description 1
- 101000649073 Homo sapiens Protein-tyrosine sulfotransferase 1 Proteins 0.000 description 1
- 101000649077 Homo sapiens Protein-tyrosine sulfotransferase 2 Proteins 0.000 description 1
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 101001000116 Homo sapiens Unconventional myosin-Ig Proteins 0.000 description 1
- 108010015268 Integration Host Factors Proteins 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091060302 Mir-320 Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 102000002488 Nucleoplasmin Human genes 0.000 description 1
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 1
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102000016187 PAZ domains Human genes 0.000 description 1
- 108050004670 PAZ domains Proteins 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 108700023158 Phenylalanine ammonia-lyases Proteins 0.000 description 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 102100029364 Piwi-like protein 1 Human genes 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102100028081 Protein-tyrosine sulfotransferase 1 Human genes 0.000 description 1
- 102100028087 Protein-tyrosine sulfotransferase 2 Human genes 0.000 description 1
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000028391 RNA cap binding Human genes 0.000 description 1
- 108091000106 RNA cap binding Proteins 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 102400000472 Sucrase Human genes 0.000 description 1
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 108010058532 UTP-hexose-1-phosphate uridylyltransferase Proteins 0.000 description 1
- 102000006321 UTP-hexose-1-phosphate uridylyltransferase Human genes 0.000 description 1
- 102100035824 Unconventional myosin-Ig Human genes 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 101150046113 XRN2 gene Proteins 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 108010060499 acharan sulfate lyase 1 Proteins 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical class O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229930192649 bafilomycin Natural products 0.000 description 1
- XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229960005347 belatacept Drugs 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 102000012012 beta Karyopherins Human genes 0.000 description 1
- 108010075890 beta Karyopherins Proteins 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 229950001178 capromab Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000021040 cytoplasmic transport Effects 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 229960002027 evolocumab Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 108010022687 fumarylacetoacetase Proteins 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 102000048307 human AGO2 Human genes 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 229960002308 idarucizumab Drugs 0.000 description 1
- 108010039650 imiglucerase Proteins 0.000 description 1
- 229960002127 imiglucerase Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 108091023663 let-7 stem-loop Proteins 0.000 description 1
- 108091063478 let-7-1 stem-loop Proteins 0.000 description 1
- 108091049777 let-7-2 stem-loop Proteins 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- WLHQHAUOOXYABV-UHFFFAOYSA-N lornoxicam Chemical compound OC=1C=2SC(Cl)=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 WLHQHAUOOXYABV-UHFFFAOYSA-N 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 108010089256 lysyl-aspartyl-glutamyl-leucine Proteins 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 108091008057 miR-10 Proteins 0.000 description 1
- 108091051410 miR-130 stem-loop Proteins 0.000 description 1
- 108091050366 miR-130-1 stem-loop Proteins 0.000 description 1
- 108091054878 miR-130-2 stem-loop Proteins 0.000 description 1
- 108091057645 miR-15 stem-loop Proteins 0.000 description 1
- 108091059964 miR-154 stem-loop Proteins 0.000 description 1
- 108091091751 miR-17 stem-loop Proteins 0.000 description 1
- 108091069239 miR-17-2 stem-loop Proteins 0.000 description 1
- 108091028751 miR-188 stem-loop Proteins 0.000 description 1
- 108091039812 miR-28 stem-loop Proteins 0.000 description 1
- 108091007431 miR-29 Proteins 0.000 description 1
- 108091074487 miR-34 stem-loop Proteins 0.000 description 1
- 108091092493 miR-34-1 stem-loop Proteins 0.000 description 1
- 108091059780 miR-34-2 stem-loop Proteins 0.000 description 1
- 108091041286 miR-374 stem-loop Proteins 0.000 description 1
- 108091027983 miR-378-1 stem-loop Proteins 0.000 description 1
- 108091089716 miR-378-2 stem-loop Proteins 0.000 description 1
- 108091079015 miR-379 Proteins 0.000 description 1
- 108091086215 miR-379 stem-loop Proteins 0.000 description 1
- 108091008052 miR-449 Proteins 0.000 description 1
- 108091087529 miR-500 stem-loop Proteins 0.000 description 1
- 108091036496 miR-500-2 stem-loop Proteins 0.000 description 1
- 108091090896 miR-506 stem-loop Proteins 0.000 description 1
- 108091091149 miR-8 stem-loop Proteins 0.000 description 1
- 108091007426 microRNA precursor Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 210000004492 nuclear pore Anatomy 0.000 description 1
- 108060005597 nucleoplasmin Proteins 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 210000000680 phagosome Anatomy 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920002851 polycationic polymer Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000004990 primary immune cell Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000013608 rAAV vector Substances 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 229960004910 raxibacumab Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000028710 ribosome assembly Effects 0.000 description 1
- 229960001886 rilonacept Drugs 0.000 description 1
- 108010046141 rilonacept Proteins 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 108010017584 romiplostim Proteins 0.000 description 1
- 229960004262 romiplostim Drugs 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
Definitions
- MicroRNAs form regulatory networks in metazoans. Viruses engage miRNA networks in numerous ways, with Flaviviridae members exploiting direct interactions of their RNA genomes with host miRNAs.
- the present invention is directed to applications of miRNA binding to stabilize RNA sequences of interest and promote their expression in specified mammalian cell types.
- the invention provides modified RNA molecules that contain a stabilizing motif or stabilizing element at the 5’ of an RNA sequence of interest (or “target RNA”).
- the stabilizing motif in the modified RNA molecules is capable of binding via base paring to a miRNA sequence that is specifically or predominantly expressed in one or several specific tissue or cell types.
- the target RNA sequence that is modified with the stabilizing motif is an mRNA encoding a polypeptide of interest (e.g., a therapeutic polypeptide).
- the stabilizing motif is complementary to the seed region of the miRNA.
- the stabilizing motif is additionally complementary to the supplementary region of the miRNA.
- the stabilizing motif contains a sequence that is substantially identical to the first 29 nucleotides at the 5’ of human HCV genome (SEQ ID NO: 1).
- the stabilizing motif contains from 5’ to 3’ (a) nucleotides 1-4 that are complementary to nucleotides 17-14 of the miRNA, wherein nucleotide 1 of the stabilizing motif is complementary to nucleotide 17 of the miRNA, (b) a hairpin of about 16 nucleotides, (c) a G nucleotide, (d) a sequence of about 7 nucleotides that are complementary to nucleotides 8-2 of the miRNA, and (e) an A nucleotide.
- the hairpin contains the sequence 5’ - gccgccugauggcggc - 3’ (SEQ ID NO:2).
- the RNA sequence of interest in the modified RNA molecules encodes a therapeutic polypeptide, an antibody or an antibody fragment.
- the invention provides methods for stabilizing a target RNA molecule in a specific tissue or cell. These methods involve (a) appending or fusing at the 5’ end of the target RNA molecule a stabilizing motif to generate a modified target RNA molecule, whereas the stabilizing motif can bind via base pairing to a miRNA that is specifically or abundantly expressed in the specific tissue or cell; and (b) introducing into the cell the modified target RNA molecule or a DNA sequence (e.g., via an expression vector) encoding the modified target RNA molecule. Typically, the target RNA molecule is uncapped or non-canonically capped prior to appending the stabilizing motif. In some preferred embodiments, the target RNA molecule is an mRNA.
- the stabilizing motif appended to the target RNA sequence is complementary to the seed region of the miRNA. In some embodiments, the stabilizing motif is further complementary to the supplementary region of the miRNA. In some embodiments, the stabilizing motif contains a sequence that is substantially identical to the first 29 nucleotides at the 5’ of human HCV genome (SEQ ID NO: 1), and the specific cell is a liver cell.
- the stabilizing motif appended to the target RNA sequence contains from 5’ to 3’ (a) nucleotides 1-4 that are complementary to nucleotides 17-14 of the miRNA (with nucleotide 1 of the target RNA being complementary to nucleotide 17 of the miRNA), (b) a hairpin structure of about 16 nucleotides, (c) a G nucleotide, (d) a sequence of about 7 nucleotides that are complementary to nucleotides 8-2 of the miRNA, and (e) an A nucleotide.
- the hairpin contains the sequence 5’- gccgccugauggcggc - 3’ (SEQ ID NO:2).
- the specific tissue or cell into which the modified target RNA molecule is to be introduced is a cancer cell, a cardiac cell or a neuron.
- the target RNA molecule encodes a therapeutic polypeptide, an antibody or an antibody fragment.
- the specific tissue or cell is brain, and the miRNA is miR-9, miR-124 or miR-128a/b.
- the specific tissue or cell is pituitary gland, and the miRNA is miR-7, miR-375, miR-141 or miR200a.
- the specific tissue or cell is thyroid or hematopoietic cell, and the miRNA is miR-142, miR-144, miR150, miR-155 or miR-223.
- the specific tissue or cell is myocardial or muscle, and the miRNA is miR-l-3p, miR-133a-3p, miR-133b or miR-206.
- the specific tissue or cell is melanocyte, and the miRNA is miR205-5p.
- the specific tissue or cell is skin, testis and colon, and the miRNA is respectively miR-205-5p, miR-514a-3p and miR-192-5p.
- the specific tissue or cell is spleen tissue, and the miRNA is miR-449c-3p or miR-449b-3p. In some other methods, the specific tissue or cell is testis tissue, and the miRNA is miR-514a-3p. In some other methods, the specific tissue or cell is kidney or small intestine, and the miRNA is miR-449c-5p or miR-449b-5p. In still some other methods, the specific tissue or cell is lung, kidney and brain, and the miRNA is miR-449a.
- the invention provides methods for expressing, or enhancing the expression of, a target RNA molecule in a specific tissue or cell. These methods entail (a) appending at the 5’ end of the target RNA molecule a stabilizing motif to generate a modified target RNA molecule, whereas the stabilizing motif is complementary to a miRNA that is specifically or abundantly expressed in the specific tissue or cell; and (b) introducing the modified target RNA molecule or a DNA sequence encoding the modified target RNA into the specific cell type.
- the target RNA molecule is exogenous to the specific tissue or cell.
- the specific tissue or cell is present in a human subject.
- the specific tissue or cell is a cancer cell, a cardiac cell or a neuron.
- the target RNA molecule encodes a therapeutic polypeptide, an antibody or an antibody fragment.
- Figure 1 shows the structure of the Ago2:miR-122:HCV RNA complex.
- A Cartoon ribbon representation of the atomic model. Shown in the panel are Ago2 protein, its globular domains (N, PAZ MID, and PIWI), miR-122, and HCV RNA. Locations of the HCV RNA 5' terminus, SL1 and G21 are indicated.
- B Cartoon schematic of miR-122:HCV RNA three-way junction.
- C Detailed schematic of base-pairing within the miR-122 (SEQ ID NO:3):HCV RNA (SEQ ID NO: 1) three-way junction.
- Figure 2 shows that HCV RNA stability is modulated by specific interactions with the Ago2-miR122 complex.
- FIG. 3 shows examples of tissue-specific expression patterns of abundant human miRNAs. Bar graphs showing the relative abundance of six different miRNAs in diverse adult human tissues. Highly expressed miRNAs are often restricted to a small set of specific tissue types. Data obtained from PMID: 26921406.
- Figure 4 illustrates a general strategy for stabilizing RNAs of interest via interactions with the Ago-miRNA complex. Shown in the figure are the stabilizing element (SEQ ID NO:4) to be added to the 5' end of the RNA of interest, and the complementary stabilizing miRNA (SEQ ID NO: 5). N indicates any nucleotide, provided the specified Watson-Crick base-pairing interactions (indicated by gray lines) are established. RNAs are numbered counting from their 5' ends. A indicates adenine nucleotide, G indicates guanine.
- Figure 5 shows enhanced expression of mRNAs appended with an miR-binding motif in HEK293 cells using exogenously supplied miRNAs.
- Figure 6 shows enhanced expression of an mRNA appended with a miR-122 binding motif in Huh-7 cells that endogenously expresses miR-122.
- the present invention provides compositions and methods for stabilizing RNA sequences and promoting their expression in specific tissue or cell types.
- the invention is predicated in part on the studies undertaken by the inventors to stabilize RNAs in specified mammalian cell types.
- HCV hepatitis C virus
- binding of liver-abundant miR-122 stabilizes the viral RNA and regulates viral translation.
- the inventors investigated the structural basis for these activities, taking into consideration that miRNAs function in complex with Argonaute (Ago) proteins.
- the crystal structure of the Ago2:miR-122:HCV complex reveals a structured RNA motif that traps Ago2 on the viral RNA, masking its 5’ end from enzymatic attack
- the trapped Ago2 can recruit host factor PCBP2, implicated in viral translation, while binding of a second Ago2:miR-122 competes with PCBP2, creating a potential molecular switch for translational control.
- Combined results revealed a viral RNA structure that modulates Ago2:miR-122 dynamics and repurposes host proteins to generate a functional analog of the mRNA cap-binding complex.
- RNA of interest cellular Argonaute (Ago) proteins
- miRNAs cellular microRNAs
- Ago proteins form a stable complex with miRNAs in most human cells.
- the inventors identified a set of parameters that, when appended to the 5' end of the RNA of interest, can recruit and trap Ago-miRNA complexes and thereby shield the 5' end of the RNA of interest from degradation by cellular exonucleases and recognition by the innate immune response.
- RNA of interest i.e., an uncapped or non-canonically capped target mRNA molecule
- RNA of interest i.e., an uncapped or non-canonically capped target mRNA molecule
- the inventors demonstrated that expressions of RNAs modified with a 5’ appended stabilizing motif in live mammalian cells are upregulated by several folds when the corresponding miRNA is either exogeneously supplied or endogenously expressed.
- the invention provides modified RNA molecules with enhanced stability in one or more specific tissue or cell types.
- the modified RNA molecules contain at its 5’ an appended stabilizing motif that can bind via base pairing to a miRNA that is specifically or abundantly expressed in the specific tissue or cell types.
- Related methods for stabilizing a target RNA sequence and for promoting its expression in one or more specific tissue or cell types are also provided in the invention.
- RNA molecules of the invention and related methods of the invention can all be generated or performed in accordance with the procedures exemplified herein or routinely practiced methods well known in the art. Unless otherwise indicated, the practice of the present invention employs conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art Such techniques are explained fully in the literature.
- agent includes any substance, molecule, element, compound, entity, or a combination thereof. It includes, but is not limited to, e.g., protein, polypeptide, small organic molecule, polysaccharide, polynucleotide, and the like. It can be a natural product, a synthetic compound, or a chemical compound, or a combination of two or more substances. Unless otherwise specified, the terms “agent”, “substance”, and “compound” are used interchangeably herein.
- complementary refers to a nucleotide or nucleotide sequence that hybridizes to a given nucleotide or nucleotide sequence.
- the nucleotide A is complementary to T and vice versa
- the nucleotide C is complementary to G and vice versa.
- the nucleotide A is complementary to the nucleotide U and vice versa
- the nucleotide C is complementary to the nucleotide G and vice versa.
- Complementary nucleotides include those that undergo Watson and Crick base pairing and those that base pair in alternative modes (non-Watson and Crick base pairing).
- the nucleotide G is complementary to the nucleotide U and vice versa
- the nucleotide A is complementary to the nucleotide G and vice versa. Therefore, in an RNA molecule, the complementary base pairs are A and U, G and C, G and U, and A and G. Other combinations, e.g., A and C or C and U, are considered to be non- complementary base pairs.
- a complementary sequence is comprised of individual nucleotides that are complementary to the individual nucleotides of a given sequence, where the complementary nucleotides are ordered such that they will pair sequentially with the nucleotides of the given sequence. Such a complementary sequence is said to be the "complement" of the given sequence.
- RNA capping refers to a highly methylated modification of the 5’ end of RNA Pol Il-transcribed RNA. It protects RNA from degradation, recruits complexes involved in RNA processing, export and translation initiation, and marks cellular mRNA as “self’ to avoid recognition by the innate immune system.
- eukaryotic mRNAs contain a cap structure - an N7-methylated guanosine linked to the first nucleotide of the RNA via a reverse 5’ to 5’ triphosphate linkage.
- the mRNA cap In addition to its essential role of cap-dependent initiation of protein synthesis, the mRNA cap also functions as a protective group from 5’ to 3’ exonuclease cleavage and a unique identifier for recruiting protein factors for pre-mRNA splicing, polyadenylation and nuclear export. It also acts as the anchor for the recruitment of initiation factors that initiate protein synthesis and the 5’ to 3’ looping of mRNA during translation.
- a great number of uncapped or non-canonically capped RNA species have been found to exist in plants and in mammals. See, e.g., Gregory et al., Dev Cell. 14: 854-66, 2008; Jiao et al., Plant Cell.
- RNA decapping refers to the removal of the cap from a capped mRNA by decapping enzymes. This usually directs mRNA to be degraded Decapping is also regulated by RNA binding proteins which promote or antagonize the recruitment of decapping complexes to the mRNA.
- miRNAs encompass a family of ⁇ 22 nucleotide (nt) noncoding RNAs that are used by the Argonaute (Ago) proteins as guides for identifying complementary sites in the messenger RNAs (mRNAs) that are targeted for repression.
- RNAs have been identified in organisms ranging from nematodes to humans. Many miRNAs are evolutionarily conserved widely across phyla, regulating gene expression by post-transcriptional gene repression. It has been estimated that the expression of more than 50% of the protein-coding genes in humans are under miRNA control.
- the long primary transcripts (pri-miRNAs) are transcribed by RNA polymerase II; processed by a nuclear enzyme Drosha; and released as a ⁇ 60bp hairpin precursor (pre-miRNAs). Pre-miRNAs are processed by RNase in enzymes, Dicer, to ⁇ 22 nt (mature miRNAs) and then incorporated into RISC (RNA-induced silencing complex). The complex of miRNAs-RISC binds the 3’ UTR of the target mRNAs and conducts translational repression or degradation of mRNAs.
- RISC RNA-induced silencing complex
- MiRNAs are categorized into families that are based on the sequence similarity, and each miRNA is able to target multiple mRNAs. The most conserved part of miRNA is located at 5'-end and is called the seed region. Guide (g) nucleotides from the seed region (g2-g7 or g2-g8) play a primary role in target recognition because more than 80% of the interactions between miRNAs and targets occur via seed pairing. However, for 20% of the miRNA-target interactions, other regions such as the supplementary region (g13-g16) of miRNA might be involved in targeting. Although the miRNAs that belong to the same family share the same seed sequence, they contain divergent 3' regions.
- miRNA nucleic acid is defined as RNA or DNA that encodes a miR as defined above, or is complementary to a nucleic acid sequence encoding a miR, or hybridizes to such RNA or DNA and remains stably bound to it under appropriate stringency conditions. Specifically included are genomic DNA, cDNA, mRNA, miRNA and antisense molecules, pri-miRNA, pre-miRNA, mature miRNA, miRNA seed sequence, as well as nucleic acids based on alternative backbones or including alternative bases. MiRNA nucleic acids can be derived from natural sources or synthesized.
- MicroRNA seed sequence "miRNA seed sequence,” “seed region” and “seed portion” are used to refer to nucleotides 2-7 or 2-8 of the mature miRNA sequence.
- the miRNA seed sequence is typically located at the 5' end of the miRNA.
- RNA-induced silencing complex RISC is responsible for the gene silencing phenomenon known as RNA interference (RNAi).
- RNAi RNA interference
- Argonaute proteins bind different classes of small non-coding RNAs, including microRNAs (miRNAs), small interfering RNAs (siRNAs) and Piwi-interacting RNAs (piRNAs). Small RNAs guide Argonaute proteins to their specific targets through sequence complementarity (base pairing), which then leads to mRNA cleavage, translation inhibition, and/or the initiation of mRNA decay.
- the Argonaute (AGO) gene family encodes for six characteristic domains: N- terminal (N), Linker-1 (L1), PAZ, Linker-2 (L2), Mid, and a C-terminal PIWI domain.
- a “host cell” refers to a living cell into which a heterologous polynucleotide sequence is to be or has been introduced.
- the living cell includes both a cultured cell and a cell within a living organism.
- Means for introducing the heterologous polynucleotide sequence into the cell are well known, e.g., transfection, electroporation, calcium phosphate precipitation, microinjection, transformation, viral infection, and/or the like.
- the heterologous polynucleotide sequence to be introduced into the cell is a replicable expression vector or cloning vector.
- host cells can be engineered to incorporate a desired gene on its chromosome or in its genome.
- CHO cells e.g., CHO cells
- host cells e.g., CHO cells
- the host cell is a mammalian cell.
- operably linked or “operably associated” refers to functional linkage between genetic elements that are joined in a manner that enables them to carry out their normal functions.
- a DNA sequence encoding a modified RNA molecule described herein is operably linked to a promoter when its transcription is under the control of the promoter and the transcript produced is correctly translated into a protein of interest that is normally encoded by the DNA gene.
- a “substantially identical” nucleic acid or amino acid sequence refers to a polynucleotide or amino acid sequence which comprises a sequence that has at least 75%, 80% or 90% sequence identity to a reference sequence as measured by one of the well-known programs described herein (e.g., BLAST) using standard parameters.
- the sequence identity is preferably at least 95%, more preferably at least 98%, and most preferably at least 99%.
- the subject sequence is of about the same length as compared to the reference sequence, i.e., consisting of about the same number of contiguous amino acid residues (for polypeptide sequences) or nucleotide residues (for polynucleotide sequences).
- Sequence identity can be readily determined with various methods known in the art.
- the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)).
- Percentage of sequence identity is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences.
- the percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.
- a cell has been “transformed” or “transfected” by exogenous or heterologous polynucleotide when such polynucleotide has been introduced inside the cell
- the transforming polynucleotide may or may not be integrated (covalently linked) into the genome of the cell.
- the transforming polynucleotide may be maintained on an episomal element such as a plasmid.
- a stably transformed cell is one in which the transforming polynucleotide has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication.
- a “clone” is a population of cells derived from a single cell or common ancestor by mitosis.
- a “cell line” is a clone of a primary cell that is capable of stable growth in vitro for many generations.
- vector refers to polynucleotide sequence elements arranged in a definite pattern of organization such that the expression of genes/gene products that are operably linked to these elements can be predictably controlled. Typically, they are transmissible polynucleotide sequences (e.g., plasmid or virus) into which a segment of foreign polynucleotide sequence can be spliced in order to introduce the foreign DNA into host cells to promote its replication and/or transcription.
- vectors capable of directing the expression of heterologous polynucleotide or target gene sequences encoding for one or more polypeptides are referred to as "expression vectors" or "expression constructs”.
- the invention provides modified or stabilized RNA molecules that can be expressed in specific tissue or cell types.
- a general strategy for obtaining such modified RNAs of the invention is shown in Figure 4.
- the modified RNAs contain an RNA of interest or “target RNA” (e.g., an mRNA encoding a therapeutic protein) and a sequence motif (or “stabilizing motif’ or “stabilizing element”) that is appended at the 5’ end of the RNA of interest.
- target RNA e.g., an mRNA encoding a therapeutic protein
- sequence motif or “stabilizing motif’ or “stabilizing element”
- the target RNA of interest is an mRNA.
- modified target RNA molecule or “modified RNA” is able to bind via base pairing to a miRNA molecule (e.g., miR-122) that is specifically or abundantly expressed in one or more target tissue or cell types (e.g., liver cells).
- miRNA molecule e.g., miR-122
- the target RNA of interest to be modified encodes a therapeutic polypeptide, an antibody or an antibody fragment.
- the miRNA to which the stabilizing motif binds can regulate gene expressions that are associated with a cellular process or disease development, e.g., tumor development.
- the sequence motif amended to the target RNA is complementary to a tissue- or cell-specific miRNA.
- the stabilizing motif is complementary to the seed region of the miRNA. In some of these embodiments, the stabilizing motif is further complementary to the supplementary region of the miRNA.
- RNA element found near the 5' terminus of the RNA genome of Hepatitis C Virus can be employed as the stabilizing motif in the invention.
- this sequence motif is able to base pair with miRNA-122, which is highly expressed in liver, associated with cholesterol metabolism and hepatocellular carcinoma, and plays an important role in HCV replication.
- HCV is a positive-strand RNA virus and human pathogen that can persist in liver cells for decades. Interactions between the HCV genomic RNA and the liver-specific miRNA miR-122 have been shown to be essential for maintaining HCV RNA abundance during viral infection (PMID: 16141076, 18621012, 19965718).
- the stabilizing motif in the modified RNA molecules of the invention contains a sequence that is substantially identical (e.g., at least 75%, 85%, 90%, 95% or 99% identical) to the first 29 nucleotides at the 5’ of human HCV genome, 5’- gcca gccg ccug augg cggc gaca cucca - 3’ (SEQ ID NO: 1).
- SEQ ID NO: 1 the first 29 nucleotides at the 5’ of human HCV genome
- nucleotides 1-4 (counting from the 5' end) of the stabilizing motif correspond to the reverse complement of nucleotides 14-17 of miR-122 (where nucleotide 1 of the modified target RNA is complementary to nucleotide 17 of the miRNA).
- the modified target RNA further has its sequence immediately after nucleotide 4 encoding an RNA hairpin structure. For example, starting at residue 5, the modified target RNA can contain the sequence: gccgccugauggcggc (SEQ ID NO:2).
- the modified target RNA has immediately following the hairpin sequence a single G nucleotide (corresponding to t9G).
- the sequence after the G nucleotide in the modified target RNA should be the reverse complement of nucleotides 2-8 of the reference miRNA.
- the final nucleotide in the appended motif of the modified target RNA is an A residue (corresponding to tlA).
- the stabilizing motif contains a sequence that is conservatively modified variant of SEQ ID NO: 1.
- the sequence of the stabilizing motif is identical to SEQ ID NO:1.
- the stabilizing motif appended at the 5’ of a target RNA is modified from the 29-nt HCV 5’ sequence (SEQ ID NO:1).
- This modified stabilizing motif is made to be complementary to the target RNA pairing site of another tissue-specific miRNA (“reference miRNA”) other than miR-122.
- sequence of the HCV derived stabilizing motif can be altered so that it is complementary to the seed and/or supplementary regions of other miRNAs.
- RNAs modified at the 5’ end with such altered stabilizing motifs are stabilized in cell types in which a given miRNA is specifically or highly expressed.
- nucleotides 1 ⁇ 4 (counting from the 5' end) of the altered stabilizing motif RNA of interest are the reverse complement of the nucleotide sequence of 14-17 of the given miRNA (where nucleotide 1 of the altered stabilizing motif is complementary to nucleotide 17 of the miRNA).
- the sequence immediately after nucleotide 4 in the altered stabilizing motif encodes an RNA hairpin structure of about 16 nucleotides.
- the hairpin sequence can immediately be followed by a single G nucleotide (corresponding to t9G).
- the sequence after the G nucleotide should be the reverse complement of nucleotides 2-8 of the given miRNA.
- the final nucleotide in the altered stabilizing element appended to the RNA of interest can be an A (corresponding to tl A).
- RNAs of interest By appending to a target RNA of interest a stabilizing motif that is complementary to various miRNAs that are specifically or abundantly expressed in different tissue or cell types, the modified RNAs of interest are stabilized in the different target tissue or cell types.
- each human cell type typically expresses one or two abundant miRNAs, which can be used as signatures for each cell type. Studies of miRNA expression patterns have shown that abundant miRNAs are often restricted to discrete human tissues.
- Notable miRNA families with high tissue specificity include, e.g., miR-378, miR-506, miR-8, miR-28, miR-15, miR-320, miR-10, miR181-, let-7, miR-17, miR-379, miR-29, miR-154, miR-30, miR-368, miR-188, miR-743, miR-34, miR-1273, miR-374, miR-130, miR-500, miR-515, miR-449, and 548. See, e.g., Lugwig et al., Nucleic Acids Res. 44(8):3865-77, 2016.
- a stabilizing motif corresponding to a miRNA that is specifically or abundantly expressed in a given cell type a target RNA can be stabilized and/or specifically expressed in many different types of tissues and cells.
- miRNAs and corresponding tissue/cell specificities include, e.g., miR-9, miR-124 and miR 128a/b in brain; miR-7, miR-375, miR-141 and miR200a in pituitary gland; miR-142, miR-144, miR150, miR-155 and miR-223 in thyroid and hematopoietic cells (vein and spleen); miR-l-3p, miR-133a-3p, miR-133b and miR-206 in myocardial tissues and muscle; miR205-5p in melanocytes, and miR-514a-3p and miR-192-5p in skin, testis and colon, respectively; miR-514a-3p in testis tissue; miR-449c-3p in spleen tissue; miR-449c-5p and miR-449b-5p in kidney and small intestine; miR-9, miR-124 and miR 128a/b in brain; miR-7, miR-375, mi
- tissue specificities of various human miRNAs can be found in, e.g., Lugwig et al., Nucleic Acids Res. 44(8):3865-77, 2016; Guo et al., Sci Rep 4, 5150, 2014; Panwar et al., Bioinformatics 33: 1554-60, 2017; McCall et al., Genome Res. 27: 1769-1781, 2017; Juzenas et al., Nucleic Acids Res. 45: 9290-9301, 2017; Pomper et al., Scientific Reports 10: 4921, 2020; Moreau et al., Arterioscler Thromb Vase Biol. 41 :2149-2167, 2021.
- Appending a target RNA sequence with a 5’ stabilizing motif can be readily performed with standard techniques of molecular biology.
- the target RNA sequence can be modified directly before being introduced into a specific cell type.
- fusing of the stabilizing motif to the target RNA sequence can be accomplished at the DNA level, i.e., by manipulating a DNA sequence that encodes the target RNA sequence.
- a modified DNA sequence that encodes the target RNA with an appended 5’ stabilizing motif can then be introduced into the desired tissue or cell type, typically via an expression construct, to promote expression of an encoded polypeptide of interest.
- the invention accordingly also provides expression constructs (RNA or DNA) that harbor or encode the modified RNAs described herein.
- the expression constructs of the invention contain or encode a modified RNA described herein, and are suitable for introducing into a target tissue or cell. They are typically circular vectors and, in addition to the stabilizing motif bearing sequence (DNA or RNA) that encodes the polypeptide of interest, can also contain selectable markers, an origin of replication, and other elements.
- the vector can contain a selection marker.
- the selection marker allows one to select for cells into which the vector has been introduced and/or stably integrated.
- the selection marker can be a polynucleotide encoding a protein or enzyme that confers to the cells visually identifiable characteristics.
- the vector can harbor a selection marker encoding Renilla luciferase reporter enzyme.
- the selection marker for identifying host cells into which the vector was introduced and/or stably integrated can be an antibiotic resistance gene.
- antibiotic resistance genes include antibiotic resistance genes for neomycin, chloramphenicol, blasticidin, hygromycin, and zeocin.
- the expression vectors of the invention can also bear other DNA sequences that may be necessary for proper RNA transcription and processing, as well as proper ribosome assembly and function.
- some vectors of the invention additionally harbor sequences corresponding to the 5’-ETS and ITS elements of the precursor RNA sequence.
- the expression constructs can be recombinantly produced with many vectors well known in the art. These include viral vectors such as recombinant adenovirus, retrovirus, lentivirus, herpesvirus, poxvirus, papilloma virus, or adeno-associated virus.
- the vectors can be present in liposomes, e.g., neutral or cationic liposomes, such as DOSPA/DOPE, DOGS/DOPE or DMRIE/DOPE liposomes, and/or associated with other molecules such as DNA-anti-DNA antibody-cationic lipid (DOTMA/DOPE) complexes.
- DOTMA/DOPE DNA-anti-DNA antibody-cationic lipid
- the expression vectors may be administered to a subject via any route including, but not limited to, intramuscular, buccal, rectal, intravenous or intracoronary routes.
- Target proteins encoded by modified RNAs containing stabilizing motif can encode any exogenous proteins or polypeptides that are desired for the specific cell type.
- the target RNA molecule encodes a therapeutic polypeptide.
- These methods can be employed in therapeutic applications for delivering and expressing the stabilizing motif-appended RNA molecules in human tissues and cells that have abundant expression of a corresponding miRNA complementary to the stabilizing motif.
- the methods of the invention can be used in the prevention and/or cure of many important human diseases, including many diseases which are not amenable to treatment by other therapies.
- a stabilized mRNA molecule of the invention can be transferred, for example to treat cancer cells, to express immunomodulatory genes to fight viral infections, or to replace a gene’s function as a result of a genetic defect.
- the exogenous mRNA (or corresponding DNA sequence) can also encode an antigen of interest for the production of antibodies.
- the exogenous sequence to be transferred with the methods of the present invention is a polynucleotide that encodes an enzyme.
- the gene can encode a cyclin-dependent kinase (CDK).
- Additional embodiments of the invention encompass transferring into target cells exogenous genes that encode cell adhesion molecules or therapeutic antibodies, other tumor suppressors such as p21 and BRCA2, inducers of apoptosis such as Bax and Bak, other enzymes such as cytosine deaminases and thymidine kinases, hormones such as growth hormone and insulin, and interleukins and cytokines.
- RNA molecules of the invention can encode an antibody or antibody fragment.
- These include many known antibody-related molecules that are well characterized in the art, e.g., CD4-Ig, eCD4-Ig, PG9, PG16, PGT121, PGT128, 10-1074, PGT145, PGT151, CAP256, 2F5, 4E10, 10E8, 3BNC117, VRC01, VRC07, VRC13, PGDM1400, PGV04, 2G12, bl2, N6, TR66, etanercept, abatacept, rilonacept, aflibercept, belatacept, romiplostim, efmoroctocog, eftrenonacog, asfotase alpha, muromonab-CD3, edrecolomab, capromab, ibritumomab, blinatumomab, abciximab
- the transgene in the expression vectors of the invention can encode at least a chain or functional fragment derived from any of the other known cellular proteins such as cellular receptors, other cell surface molecules, enzymes, cytokines, chemokines, costimulatory molecules, interleukins, and physiologically active polypeptide factors.
- these known cellular proteins include, e.g., CD4, TPST1, TPST2, TNFR II, CD28, CTLA-4, PD-1, PD-L1, PD-L2, 4-1BBL, 4-1BB, EPO, Factor VIII, Factor IX, alkaline phosphatase, hemoglobin, fetal hemoglobin, and RPE65.
- the polypeptide expressed from the rAAV vectors of the invention is at least part of a chimeric antigen receptor (CAR).
- RNA molecules of the invention can encode one or more other therapeutic polypeptide agents that are well-known known in the art. These include factor VIII, factor IX, ⁇ -globin, low-density lipoprotein receptor, adenosine deaminase, purine nucleoside phosphorylase, sphingomyelinase, glucocerebrosidase, cystic fibrosis transmembrane conductance regulator, a-antitrypsin, CD-18, ornithine transcarbamylase, argininosuccinate synthetase, phenylalanine hydroxylase, branched-chain a-ketoacid dehydrogenase, fumarylacetoacetate hydrolase, glucose 6-phosphatase, a-L-fucosidase, ⁇ - glucuronidase, a-L-iduronidase, galactose 1 -phosphate uridyltransferase
- pathogens e.g., E. coli, P. aeruginosa, S. aureus, malaria, HIV, rabies virus, HBV, and cytomegalovirus
- proteins such as lactoferrin, thioredoxin and beta-casein.
- therapeutic agents or proteins of interest include, but are not limited to, insulin, erythropoietin, tissue plasminogen activator (tPA), urokinase, streptokinase, neutropoiesis stimulating protein (also known as filgastim or granulocyte colony stimulating factor (G-CSF)), thrombopoietin (TPO), growth hormone, emoglobin, insulinotropin, imiglucerase, sarbramostim, endothelian, soluble CD4, and antibodies and/or antigen-binding fragments (e g., FAbs) thereof (e g., orthoclone OKT-e (anti-CD3), GPIIb/IIa monoclonal antibody), ciliary neurite transforming factor (CNTF), granulocyte macrophage colony stimulating factor (GM-CSF), brain-derived neurite factor (BDNF), parathyroid hormone(PTH)-like hormone, insulinotrophic hormone, insulin-like
- the invention provides methods of stabilizing or enhancing stability of an RNA molecule in selected tissue or cell types.
- the methods utilize modified RNAs that contain an appended stabilizing motif as described above.
- the stabilizing motif can enable the target RNA to bind to a miRNA molecule specifically or predominantly expressed in one or several specific tissue or cell types.
- Binding by the miRNA to the modified target RNA molecule protects it from degradation by cellular exonucleases (primarily XRN-1 and XRN-2), thereby stabilizing the target RNAs in the specific tissue- or cell- types.
- RNAs lacking a canonical 5' cap structure are subject to degradation by the cellular exonucleases.
- cells or tissues lacking the specified miRNA will be unable to accumulate the target RNA of interest.
- the invention also provides methods of promoting or enhancing expression of a target RNA (e g , an mRNA) in a specific or specified cell type.
- a target RNA e g , an mRNA
- the target RNA is modified by fusing or appending at its 5’ a stabilizing motif that specifically binds to a miRNA.
- the target RNA molecule thus modified (or its encoding DNA sequence) is introduced into a specific cell type (e g., liver cell) in which the corresponding miRNA (e.g., miR-122) is differentially or abundantly expressed.
- the stabilizing element may be appended to the 5' end of any uncapped or non-canonically capped RNA for which accumulation in specific cell types is desired. If placed upstream of an appropriate Internal Ribosomal Entry Site (IRES), the stabilizing element may enable exogenous mRNAs to be expressed in specified cell types (e g., cancer cells, cardiac cells, neurons, etc.).
- IRS Internal Ribosomal Entry Site
- a stabilizing motif bearing RNA of interest can be directly introduced into a corresponding specific cell type via standard techniques of molecule biology.
- delivering a modified exogenous RNA sequence into the specific cell type is achieved by first generating a DNA sequence encoding the stabilized RNA and then introducing the DNA sequence (e.g., via suitable expression vector) into the desired specific cell type.
- the modified RNA molecules of the invention or DNA sequences encoding the same can be delivered to specific tissues or cells with various methods well known in the art.
- a transfection agent is used.
- a transfection agent, or transfection reagent or delivery vehicle is a compound that binds to or complexes with oligonucleotides and polynucleotides, and enhances their entry into cells.
- transfection reagents include, but are not limited to, cationic liposomes and lipids, polyamines, calcium phosphate precipitates, polycations, histone proteins, polyethylenimine, polylysine, and polyampholyte complexes.
- Transfection reagents are well known in the art. Examples of transfection reagents suitable for delivery of mRNA molecules include MagicTM mRNA Transfection Reagent (Creative Biolabs) and in vivo-jetRNA® (Polyplus).
- Reagents for delivery of modified target RNA molecules of the invention or their encoding DNA sequences into specific tissue or cells include, but are not limited to protein and polymer complexes (polyplexes), lipids and liposomes (lipoplexes), combinations of polymers and lipids (lipopolyplexes), and multilayered and recharged particles.
- Transfection agents may also condense nucleic acids. Transfection agents may also be used to associate functional groups with a polynucleotide.
- Functional groups can include cell targeting moieties, cell receptor ligands, nuclear localization signals, compounds that enhance release of contents from endosomes or other intracellular vesicles (such as membrane active compounds), and other compounds that alter the behavior or interactions of the compound or complex to which they are attached (interaction modifiers).
- complexes made with sub-neutralizing amounts of cationic transfection agent may be preferred.
- polycations are mixed with polynucleotides for delivery to a cell.
- Poly cations are a very convenient linker for attaching specific receptors to DNA and as result, DNA/polycation complexes can be targeted to specific cell types.
- An endocytic step in the intracellular uptake of DNA/polycation complexes is suggested by results in which functional DNA delivery is increased by incorporating endosome disruptive capability into the polycation transfection vehicle.
- Polycations also cause DNA condensation.
- the volume which one DNA molecule occupies in complex with polycations is drastically lower than the volume of a free DNA molecule.
- the size of DNA/polymer complex may be important for gene delivery in vivo.
- Polymer reagents for delivery of a nucleic acid molecule may incorporate compounds that increase their utility. These groups can be incorporated into monomers prior to polymer formation or attached to polymers after their formation.
- An anti-miRNA transfer enhancing moiety is typically a molecule that modifies a nucleic acid complex and can direct it to a cell location (such as tissue cells) or location in a cell (such as the nucleus) either in culture or in a whole organism. By modifying the cellular or tissue location of the complex, the desired localization and activity of the polynucleotide can be enhanced.
- the transfer enhancing moiety can be, for example, a protein, peptide, lipid, steroid, sugar, carbohydrate, nucleic acid, cell receptor ligand, or synthetic compound.
- the transfer enhancing moi eties can enhance cellular binding to receptors, cytoplasmic transport to the nucleus and nuclear entry or release from endosomes or other intracellular vesicles.
- Nuclear localizing signals can also be used to enhance the targeting of the nucleic acid molecule into proximity of the nucleus and/or its entry into the nucleus.
- Such nuclear transport signals can be a protein or a peptide such as the SV40 large Tag NLS or the nucleoplasmin NLS.
- These nuclear localizing signals interact with a variety of nuclear transport factors such as the NLS receptor (karyopherin alpha) which then interacts with karyopherin beta.
- the nuclear transport proteins themselves could also function as NLS's since they are targeted to the nuclear pore and nucleus.
- Compounds that enhance release from intracellular compartments can cause DNA release from intracellular compartments such as endosomes (early and late), lysosomes, phagosomes, vesicle, endoplasmic reticulum, Golgi apparatus, trans Golgi network (TGN), and sarcoplasmic reticulum and could be used to aid delivery of the anti-miRNA molecule.
- Endosomes early and late
- lysosomes lysosomes
- phagosomes phagosomes
- vesicle endoplasmic reticulum
- Golgi apparatus Golgi apparatus
- TGN trans Golgi network
- sarcoplasmic reticulum sarcoplasmic reticulum
- Such compounds include chemicals such as chloroquine, bafilomycin or Brefeldin Al and the ER-retaining signal (KDEL sequence), viral components such as influenza virus hemagglutinin subunit HA-2 peptides and other types of amphipathic peptides.
- chemicals such as chloroquine, bafilomycin or Brefeldin Al and the ER-retaining signal (KDEL sequence)
- viral components such as influenza virus hemagglutinin subunit HA-2 peptides and other types of amphipathic peptides.
- Cellular receptor moieties are any signal that enhances the association of the nucleic acid molecule with a cell. Enhanced cellular association can be accomplished by either increasing the binding of the polynucleotide or polynucleotide complex to the cell surface and/or its association with an intracellular compartment, for example: ligands that enhance endocytosis by enhancing binding the cell surface.
- Cellular receptor moieties include agents that target to asialoglycoprotein receptors by using asialoglycoproteins or galactose residues. Other proteins such as insulin, EGF, or transferrin can be used for targeting. Peptides that include the RGD sequence can also be used to target many cells.
- Chemical groups that react with sulfhydryl or disulfide groups on cells can also be used to target many types of cells.
- Folate and other vitamins can also be used for targeting.
- Other targeting groups include molecules that interact with membranes such as lipids fatty acids, cholesterol, dansyl compounds, and amphotericin derivatives.
- viral proteins could be used to target cells.
- the invention further provides engineered mammalian cells which express a modified RNA sequence described herein.
- Various mammalian cells can be employed for introducing an expression construct of the invention or by stably integrating the rDNA described herein into the host genome.
- Polynucleotides containing or encoding the modified RNA can be introduced into an appropriate host cell (e.g., a mammalian cell such as 293T cell, N2a cell or CHO cell, or PBMC, or primary immune cells) by any means known in the art.
- the cells can transiently or stably express the introduced vectors containing or encoding the target RNA.
- mammalian cells are used in these embodiments of the invention.
- Mammalian expression systems allow for proper post-translational modifications of expressed mammalian proteins to occur, e.g., proper processing of the primary transcript, glycosylation, phosphorylation and advantageously secretion of expressed product.
- Suitable cells include cells rodent, cow, goat, rabbit, sheep, non-human primate, human, and the like).
- Specific examples of cell lines include CHO, BHK, HEK293, N2a, VERO, HeLa, COS, MDCK, and W138. Any convenient protocol may be employed for in vitro or in vivo introduction of the expression vector into the host cell, depending on the location of the host cell.
- the expression construct may be introduced directly into the cell under cell culture conditions permissive of viability of the host cell, e.g., by using standard transformation techniques.
- the crystal structure shows base-pairing interactions between the HCV RNA and miR-122. Specifically, nucleotides 2-8 and 14-17 of miR-122 (counting from the 5' end of miR-122) pair with the HCV RNA, forming two RNA duplex regions termed ‘seed duplex’ and ‘supplementary duplex’, respectively ( Figure 1). Seed and supplementary duplexes are separated by a stem -loop structure (SL1) in the HCV RNA, thereby forming a three-way RNA junction.
- SL1 stem -loop structure
- the crystal structure also shows contacts between Ago2 and the HCV RNA.
- SL1 of the HCV RNA inserts between the Ago2 PIWI and PAZ domains, locking Ago2 in an opened conformation.
- HCV nucleotide G21 (corresponding to the ‘t9’ position in miRNA- targeting nomenclature) inserts into a surface pocket in the Ago2 PIWI domain, termed the t9G-binding pocket.
- HCV nucleotide A29 inserts into a binding pocket in the Ago2 MID domain termed the tlA-binding pocket (PMID: 26359634).
- Example 2 Defined contacts to Ago2-miR122 stabilize the HCV RNA
- Example 3 Human miRNAs display discrete and diverse expression patterns [0070] Studies of miRNA expression patterns have shown that abundant miRNAs are often restricted to discrete human tissues (PMID: 26921406). Tumors and cancer cells also often display unique miRNA expression patterns. Thus, in many cases, expression of a particular miRNA may be used as a molecular signature for a specific cell type ( Figure 3).
- Example 4 Expressing stabilized exogenous mRNAs in specific cell types [0071] This example describes expression of exogenous mRNAs appended with a stabilizing motif in a specific cell type in the presence of corresponding miRNAs. [0072] We first tested expression of modified mRNAs in HEK293 cells with exogeneously introduced miRNAs that are recognized by the 5’ stabilizing motif in the modified mRNAs. Specifically, uncapped mRNAs, encoding a luciferase reporter gene, were produced with stabilizing elements specific to either miRNA-A or miRNA-B (two artificial miRNAs, not naturally present in HEK293 cells).
- mRNAs were transfected into HEK293 cells with miRNA-A, or miRNA-B, or no exogenous miRNA. Expression levels of the luciferase reporter were subsequently measured in each sample ( Figure 5, A). The results indicate that co-transfection of the mRNA containing a stabilizing element recognized by miRNA-A with miRNA-A led to approximately 10 times more luciferase activity than transfection of the same mRNA without a miRNA or with miRNA-B, demonstrating upregulation dependent on recognition by miRNA-A (( Figure 5, B, right). Similarly, the presence of miRNA-B promoted the expression of the mRNA containing a stabilizing element specifically recognized by miRNA-B ( Figure 5, B, left). These results indicate that the miRNA-specific stabilizing effects observed in vitro are recapitulated in living cells.
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides modified RNA molecules with enhanced stability in one or more specific tissue or cell types. The modified RNA molecules contain at its 5' an appended stabilizing motif that can bind via base pairing to a miRNA that is specifically or abundantly expressed in the specific tissue or cell types. Related methods for stabilizing a target RNA sequence and for promoting its expression in one or more specific tissue or cell types are also provided in the invention.
Description
Stabilizing RNAs With miRNA-Binding Motifs
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The subject patent application claims the benefit of priority to U.S. Provisional Patent Application No. 63/392,393 (filed July 26, 2022; now pending). The full disclosure of the priority application is incorporated herein by reference in its entirety and for all purposes.
STATEMENT OF GOVERNMENT SUPPORT
[0002] This invention was made with government support under GM127090 awarded by the National Institutes of Health. The government has certain rights in this invention.
BACKGROUND OF THE INVENTION
[0003] MicroRNAs (miRNAs) form regulatory networks in metazoans. Viruses engage miRNA networks in numerous ways, with Flaviviridae members exploiting direct interactions of their RNA genomes with host miRNAs. The present invention is directed to applications of miRNA binding to stabilize RNA sequences of interest and promote their expression in specified mammalian cell types.
SUMMARY OF THE INVENTION
[0004] In one aspect, the invention provides modified RNA molecules that contain a stabilizing motif or stabilizing element at the 5’ of an RNA sequence of interest (or “target RNA”). The stabilizing motif in the modified RNA molecules is capable of binding via base paring to a miRNA sequence that is specifically or predominantly expressed in one or several specific tissue or cell types. In some embodiments, the target RNA sequence that is modified with the stabilizing motif is an mRNA encoding a polypeptide of interest (e.g., a therapeutic polypeptide). Typically, the stabilizing motif is complementary to the seed region of the miRNA. In some embodiments, the stabilizing motif is additionally complementary to the supplementary region of the miRNA.
[0005] In some modified RNA molecules of the invention, the stabilizing motif contains a sequence that is substantially identical to the first 29 nucleotides at the 5’ of human HCV genome (SEQ ID NO: 1). In some embodiments, the stabilizing motif contains from 5’ to 3’
(a) nucleotides 1-4 that are complementary to nucleotides 17-14 of the miRNA, wherein nucleotide 1 of the stabilizing motif is complementary to nucleotide 17 of the miRNA, (b) a hairpin of about 16 nucleotides, (c) a G nucleotide, (d) a sequence of about 7 nucleotides that are complementary to nucleotides 8-2 of the miRNA, and (e) an A nucleotide. In some of these embodiments, the hairpin contains the sequence 5’ - gccgccugauggcggc - 3’ (SEQ ID NO:2). In various embodiments, the RNA sequence of interest in the modified RNA molecules encodes a therapeutic polypeptide, an antibody or an antibody fragment.
[0006] In another aspect, the invention provides methods for stabilizing a target RNA molecule in a specific tissue or cell. These methods involve (a) appending or fusing at the 5’ end of the target RNA molecule a stabilizing motif to generate a modified target RNA molecule, whereas the stabilizing motif can bind via base pairing to a miRNA that is specifically or abundantly expressed in the specific tissue or cell; and (b) introducing into the cell the modified target RNA molecule or a DNA sequence (e.g., via an expression vector) encoding the modified target RNA molecule. Typically, the target RNA molecule is uncapped or non-canonically capped prior to appending the stabilizing motif. In some preferred embodiments, the target RNA molecule is an mRNA. In general, the stabilizing motif appended to the target RNA sequence is complementary to the seed region of the miRNA. In some embodiments, the stabilizing motif is further complementary to the supplementary region of the miRNA. In some embodiments, the stabilizing motif contains a sequence that is substantially identical to the first 29 nucleotides at the 5’ of human HCV genome (SEQ ID NO: 1), and the specific cell is a liver cell. In some methods, the stabilizing motif appended to the target RNA sequence contains from 5’ to 3’ (a) nucleotides 1-4 that are complementary to nucleotides 17-14 of the miRNA (with nucleotide 1 of the target RNA being complementary to nucleotide 17 of the miRNA), (b) a hairpin structure of about 16 nucleotides, (c) a G nucleotide, (d) a sequence of about 7 nucleotides that are complementary to nucleotides 8-2 of the miRNA, and (e) an A nucleotide. In some of these embodiments, the hairpin contains the sequence 5’- gccgccugauggcggc - 3’ (SEQ ID NO:2).
[0007] In various embodiments, the specific tissue or cell into which the modified target RNA molecule is to be introduced is a cancer cell, a cardiac cell or a neuron. In some of these methods, the target RNA molecule encodes a therapeutic polypeptide, an antibody or an antibody fragment. In some methods, the specific tissue or cell is brain, and the miRNA is miR-9, miR-124 or miR-128a/b. In some methods, the specific tissue or cell is pituitary gland, and the miRNA is miR-7, miR-375, miR-141 or miR200a. In some methods, the
specific tissue or cell is thyroid or hematopoietic cell, and the miRNA is miR-142, miR-144, miR150, miR-155 or miR-223. In some methods, the specific tissue or cell is myocardial or muscle, and the miRNA is miR-l-3p, miR-133a-3p, miR-133b or miR-206. In some methods, the specific tissue or cell is melanocyte, and the miRNA is miR205-5p. In some methods, the specific tissue or cell is skin, testis and colon, and the miRNA is respectively miR-205-5p, miR-514a-3p and miR-192-5p. In some methods, the specific tissue or cell is spleen tissue, and the miRNA is miR-449c-3p or miR-449b-3p. In some other methods, the specific tissue or cell is testis tissue, and the miRNA is miR-514a-3p. In some other methods, the specific tissue or cell is kidney or small intestine, and the miRNA is miR-449c-5p or miR-449b-5p. In still some other methods, the specific tissue or cell is lung, kidney and brain, and the miRNA is miR-449a.
[0008] In a related aspect, the invention provides methods for expressing, or enhancing the expression of, a target RNA molecule in a specific tissue or cell. These methods entail (a) appending at the 5’ end of the target RNA molecule a stabilizing motif to generate a modified target RNA molecule, whereas the stabilizing motif is complementary to a miRNA that is specifically or abundantly expressed in the specific tissue or cell; and (b) introducing the modified target RNA molecule or a DNA sequence encoding the modified target RNA into the specific cell type. In some embodiments, the target RNA molecule is exogenous to the specific tissue or cell. In some embodiments, the specific tissue or cell is present in a human subject. In some methods, the specific tissue or cell is a cancer cell, a cardiac cell or a neuron. In some methods, the target RNA molecule encodes a therapeutic polypeptide, an antibody or an antibody fragment.
[0009] A further understanding of the nature and advantages of the present invention may be realized by reference to the remaining portions of the specification and claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 shows the structure of the Ago2:miR-122:HCV RNA complex. (A) Cartoon ribbon representation of the atomic model. Shown in the panel are Ago2 protein, its globular domains (N, PAZ MID, and PIWI), miR-122, and HCV RNA. Locations of the HCV RNA 5' terminus, SL1 and G21 are indicated. (B) Cartoon schematic of miR-122:HCV RNA three-way junction. C. Detailed schematic of base-pairing within the miR-122 (SEQ ID NO:3):HCV RNA (SEQ ID NO: 1) three-way junction.
[0011] Figure 2 shows that HCV RNA stability is modulated by specific interactions with the Ago2-miR122 complex. (A) Plot of intact RNA corresponding to 5'UTR of the HCV genome treated with XRN-1 in the presence or absence of the Ago2-miR122 complex versus time. (B) Plot of intact HCV 5'UTR RNA mutants in the presence of XRN-1 and Ago2- miR122. Mutations were designed to disrupt base pairing in the seed duplex (Aseed), supplementary duplex (Asup), or SL1 (ASL1). (C) Plot of wild-type and mutant HCV RNA levels (assessed by RT-PCR) after transfection into Huh-7.5.1 cells versus time.
[0012] Figure 3 shows examples of tissue-specific expression patterns of abundant human miRNAs. Bar graphs showing the relative abundance of six different miRNAs in diverse adult human tissues. Highly expressed miRNAs are often restricted to a small set of specific tissue types. Data obtained from PMID: 26921406.
[0013] Figure 4 illustrates a general strategy for stabilizing RNAs of interest via interactions with the Ago-miRNA complex. Shown in the figure are the stabilizing element (SEQ ID NO:4) to be added to the 5' end of the RNA of interest, and the complementary stabilizing miRNA (SEQ ID NO: 5). N indicates any nucleotide, provided the specified Watson-Crick base-pairing interactions (indicated by gray lines) are established. RNAs are numbered counting from their 5' ends. A indicates adenine nucleotide, G indicates guanine. [0014] Figure 5 shows enhanced expression of mRNAs appended with an miR-binding motif in HEK293 cells using exogenously supplied miRNAs.
[0015] Figure 6 shows enhanced expression of an mRNA appended with a miR-122 binding motif in Huh-7 cells that endogenously expresses miR-122.
DETAILED DESCRIPTION OF THE INVENTION
I. Overview
[0016] The present invention provides compositions and methods for stabilizing RNA sequences and promoting their expression in specific tissue or cell types. The invention is predicated in part on the studies undertaken by the inventors to stabilize RNAs in specified mammalian cell types. For hepatitis C virus (HCV), binding of liver-abundant miR-122 stabilizes the viral RNA and regulates viral translation. The inventors investigated the structural basis for these activities, taking into consideration that miRNAs function in complex with Argonaute (Ago) proteins. The crystal structure of the Ago2:miR-122:HCV complex reveals a structured RNA motif that traps Ago2 on the viral RNA, masking its 5’ end from enzymatic attack The trapped Ago2 can recruit host factor PCBP2, implicated in
viral translation, while binding of a second Ago2:miR-122 competes with PCBP2, creating a potential molecular switch for translational control. Combined results revealed a viral RNA structure that modulates Ago2:miR-122 dynamics and repurposes host proteins to generate a functional analog of the mRNA cap-binding complex.
[0017] As detailed herein, the inventors employed specific interactions between the RNA of interest, cellular Argonaute (Ago) proteins, and cellular microRNAs (miRNAs). Ago proteins form a stable complex with miRNAs in most human cells. The inventors identified a set of parameters that, when appended to the 5' end of the RNA of interest, can recruit and trap Ago-miRNA complexes and thereby shield the 5' end of the RNA of interest from degradation by cellular exonucleases and recognition by the innate immune response.
Specificity is achieved through base-pairing interactions between the RNA of interest and the miRNA. The human genome encodes hundreds of different miRNAs, which have unique nucleotide sequences and distinct expression patterns in different mammalian cell types. Therefore, by leveraging miRNA expression diversity, the RNA of interest (i.e., an uncapped or non-canonically capped target mRNA molecule) can be designed to be stable in targeted cell types while remaining unstable in all others. As exemplifications, the inventors demonstrated that expressions of RNAs modified with a 5’ appended stabilizing motif in live mammalian cells are upregulated by several folds when the corresponding miRNA is either exogeneously supplied or endogenously expressed.
[0018] In accordance with the studies exemplified herein, the invention provides modified RNA molecules with enhanced stability in one or more specific tissue or cell types. The modified RNA molecules contain at its 5’ an appended stabilizing motif that can bind via base pairing to a miRNA that is specifically or abundantly expressed in the specific tissue or cell types. Related methods for stabilizing a target RNA sequence and for promoting its expression in one or more specific tissue or cell types are also provided in the invention.
[0019] It is noted that this invention is not limited to the particular methodology, protocols, and reagents described as these may vary. The modified RNA molecules of the invention and related methods of the invention can all be generated or performed in accordance with the procedures exemplified herein or routinely practiced methods well known in the art. Unless otherwise indicated, the practice of the present invention employs conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art Such techniques are explained fully in the literature. For example, exemplary methods are
described in the following references, Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (3rd ed., 2001); Brent et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (ringbou ed., 2003); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (1986); or Methods in Enzymology: Guide to Molecular Cloning Techniques Vol. 152, S. L. Berger and A. R. Kimmerl Eds., Academic Press Inc., San Diego, USA (1987); Current Protocols in Protein Science (CPPS) (John E. Coligan, et. al., ed., John Wiley and Sons, Inc.), Current Protocols in Cell Biology (CPCB) (Juan S. Bonifacino et. al. ed., John Wiley and Sons, Inc.), and Culture of Animal Cells: A Manual of Basic Technique by R. Ian Freshney, Publisher: Wiley-Liss; 5th edition (2005), Animal Cell Culture Methods (Methods in Cell Biology, Vol. 57, Jennie P. Mather and David Barnes editors, Academic Press, 1st edition, 1998).
[0020] The following sections provide additional guidance for practicing the compositions and methods of the present invention.
II. Definitions
[0021] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention pertains. The following references provide one of skill with a general definition of many of the terms used in this invention: Academic Press Dictionary of Science and Technology, Morris (Ed.), Academic Press (1st ed., 1992); Oxford Dictionary of Biochemistry and Molecular Biology, Smith et al. (Eds.), Oxford University Press (revised ed., 2000); Encyclopaedic Dictionary of Chemistry, Kumar (Ed.), Anmol Publications Pvt. Ltd. (2002); Dictionary of Microbiology and Molecular Biology, Singleton et al. (Eds ), John Wiley & Sons
ed., 2002); Dictionary of Chemistry, Hunt (Ed.), Routledge (1st ed., 1999); Dictionary of Pharmaceutical Medicine, Nahler (Ed.), Springer-Verlag Telos (1994);
Dictionary of Organic Chemistry, Kumar and Anandand (Eds.), Anmol Publications Pvt. Ltd. (2002); and A Dictionary of Biology (Oxford Paperback Reference), Martin and Hine (Eds.), Oxford University Press (4th ed., 2000). In addition, the following definitions are provided to assist the reader in the practice of the invention.
[0022] As used herein, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells, reference to "a protein" includes one or more proteins and equivalents thereof known to those skilled in the art, and so forth.
[0023] The term "agent" includes any substance, molecule, element, compound, entity, or a combination thereof. It includes, but is not limited to, e.g., protein, polypeptide, small organic molecule, polysaccharide, polynucleotide, and the like. It can be a natural product, a synthetic compound, or a chemical compound, or a combination of two or more substances. Unless otherwise specified, the terms “agent”, “substance”, and “compound” are used interchangeably herein.
[0024] As used herein, complementary refers to a nucleotide or nucleotide sequence that hybridizes to a given nucleotide or nucleotide sequence. For instance, for DNA, the nucleotide A is complementary to T and vice versa, and the nucleotide C is complementary to G and vice versa. For instance, in RNA, the nucleotide A is complementary to the nucleotide U and vice versa, and the nucleotide C is complementary to the nucleotide G and vice versa. Complementary nucleotides include those that undergo Watson and Crick base pairing and those that base pair in alternative modes (non-Watson and Crick base pairing). For instance, as used herein for RNA, the nucleotide G is complementary to the nucleotide U and vice versa, and the nucleotide A is complementary to the nucleotide G and vice versa. Therefore, in an RNA molecule, the complementary base pairs are A and U, G and C, G and U, and A and G. Other combinations, e.g., A and C or C and U, are considered to be non- complementary base pairs. A complementary sequence is comprised of individual nucleotides that are complementary to the individual nucleotides of a given sequence, where the complementary nucleotides are ordered such that they will pair sequentially with the nucleotides of the given sequence. Such a complementary sequence is said to be the "complement" of the given sequence.
[0025] RNA capping refers to a highly methylated modification of the 5’ end of RNA Pol Il-transcribed RNA. It protects RNA from degradation, recruits complexes involved in RNA processing, export and translation initiation, and marks cellular mRNA as “self’ to avoid recognition by the innate immune system. Typically, eukaryotic mRNAs contain a cap structure - an N7-methylated guanosine linked to the first nucleotide of the RNA via a reverse 5’ to 5’ triphosphate linkage. In addition to its essential role of cap-dependent initiation of protein synthesis, the mRNA cap also functions as a protective group from 5’ to 3’ exonuclease cleavage and a unique identifier for recruiting protein factors for pre-mRNA splicing, polyadenylation and nuclear export. It also acts as the anchor for the recruitment of initiation factors that initiate protein synthesis and the 5’ to 3’ looping of mRNA during translation. A great number of uncapped or non-canonically capped RNA species have been
found to exist in plants and in mammals. See, e.g., Gregory et al., Dev Cell. 14: 854-66, 2008; Jiao et al., Plant Cell. 20: 2571-85, 2008; and Karginov et al., Mol Cell. 38: 781-8, 2010. [0026] RNA decapping refers to the removal of the cap from a capped mRNA by decapping enzymes. This usually directs mRNA to be degraded Decapping is also regulated by RNA binding proteins which promote or antagonize the recruitment of decapping complexes to the mRNA.
[0027] When used herein the terms "miR" and "miRNA" are used to refer to microRNA, a class of small RNA molecules that are capable of modulating RNA translation (see, Zeng and Cullen, RNA, 9:112-123, 2003; Kidner and Martienssen Trends Genet, 19:13-6, 2003; Dennis C, Nature, 420:732, 2002; and Couzin J, Science 298:2296-7, 2002). miRNAs encompass a family of ~22 nucleotide (nt) noncoding RNAs that are used by the Argonaute (Ago) proteins as guides for identifying complementary sites in the messenger RNAs (mRNAs) that are targeted for repression. These RNAs have been identified in organisms ranging from nematodes to humans. Many miRNAs are evolutionarily conserved widely across phyla, regulating gene expression by post-transcriptional gene repression. It has been estimated that the expression of more than 50% of the protein-coding genes in humans are under miRNA control. The long primary transcripts (pri-miRNAs) are transcribed by RNA polymerase II; processed by a nuclear enzyme Drosha; and released as a ~60bp hairpin precursor (pre-miRNAs). Pre-miRNAs are processed by RNase in enzymes, Dicer, to ~22 nt (mature miRNAs) and then incorporated into RISC (RNA-induced silencing complex). The complex of miRNAs-RISC binds the 3’ UTR of the target mRNAs and conducts translational repression or degradation of mRNAs.
[0028] MiRNAs are categorized into families that are based on the sequence similarity, and each miRNA is able to target multiple mRNAs. The most conserved part of miRNA is located at 5'-end and is called the seed region. Guide (g) nucleotides from the seed region (g2-g7 or g2-g8) play a primary role in target recognition because more than 80% of the interactions between miRNAs and targets occur via seed pairing. However, for 20% of the miRNA-target interactions, other regions such as the supplementary region (g13-g16) of miRNA might be involved in targeting. Although the miRNAs that belong to the same family share the same seed sequence, they contain divergent 3' regions. A functional redundancy has been described for representatives of the same family; however, there are also some examples in which a single miRNA recognizes a specific gene.
[0029] As used herein, "miRNA nucleic acid" is defined as RNA or DNA that encodes a miR as defined above, or is complementary to a nucleic acid sequence encoding a miR, or hybridizes to such RNA or DNA and remains stably bound to it under appropriate stringency conditions. Specifically included are genomic DNA, cDNA, mRNA, miRNA and antisense molecules, pri-miRNA, pre-miRNA, mature miRNA, miRNA seed sequence, as well as nucleic acids based on alternative backbones or including alternative bases. MiRNA nucleic acids can be derived from natural sources or synthesized.
[0030] MicroRNA seed sequence," "miRNA seed sequence," "seed region" and "seed portion" are used to refer to nucleotides 2-7 or 2-8 of the mature miRNA sequence. The miRNA seed sequence is typically located at the 5' end of the miRNA.
[0031] The Argonaute protein family, first discovered for its evolutionarily conserved stem cell function, plays a central role in RNA silencing processes as essential components of the RNA-induced silencing complex (RISC). RISC is responsible for the gene silencing phenomenon known as RNA interference (RNAi). Argonaute proteins bind different classes of small non-coding RNAs, including microRNAs (miRNAs), small interfering RNAs (siRNAs) and Piwi-interacting RNAs (piRNAs). Small RNAs guide Argonaute proteins to their specific targets through sequence complementarity (base pairing), which then leads to mRNA cleavage, translation inhibition, and/or the initiation of mRNA decay. The Argonaute (AGO) gene family encodes for six characteristic domains: N- terminal (N), Linker-1 (L1), PAZ, Linker-2 (L2), Mid, and a C-terminal PIWI domain.
[0032] A “host cell” refers to a living cell into which a heterologous polynucleotide sequence is to be or has been introduced. The living cell includes both a cultured cell and a cell within a living organism. Means for introducing the heterologous polynucleotide sequence into the cell are well known, e.g., transfection, electroporation, calcium phosphate precipitation, microinjection, transformation, viral infection, and/or the like. Often, the heterologous polynucleotide sequence to be introduced into the cell is a replicable expression vector or cloning vector. In some embodiments, host cells can be engineered to incorporate a desired gene on its chromosome or in its genome. Many host cells that can be employed in the practice of the present invention (e.g., CHO cells) serve as hosts are well known in the art See, e g , Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (3rd ed., 2001); and Brent et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (ringbou ed., 2003). In some preferred embodiments, the host cell is a mammalian cell.
[0033] The term “operably linked” or “operably associated” refers to functional linkage between genetic elements that are joined in a manner that enables them to carry out their normal functions. For example, a DNA sequence encoding a modified RNA molecule described herein is operably linked to a promoter when its transcription is under the control of the promoter and the transcript produced is correctly translated into a protein of interest that is normally encoded by the DNA gene.
[0034] A “substantially identical” nucleic acid or amino acid sequence refers to a polynucleotide or amino acid sequence which comprises a sequence that has at least 75%, 80% or 90% sequence identity to a reference sequence as measured by one of the well-known programs described herein (e.g., BLAST) using standard parameters. The sequence identity is preferably at least 95%, more preferably at least 98%, and most preferably at least 99%. In some embodiments, the subject sequence is of about the same length as compared to the reference sequence, i.e., consisting of about the same number of contiguous amino acid residues (for polypeptide sequences) or nucleotide residues (for polynucleotide sequences). [0035] Sequence identity can be readily determined with various methods known in the art. For example, the BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)). Percentage of sequence identity is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. [0036] A cell has been “transformed” or “transfected” by exogenous or heterologous polynucleotide when such polynucleotide has been introduced inside the cell The transforming polynucleotide may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming polynucleotide may be maintained on an episomal element such as a plasmid.
With respect to eukaryotic cells, a stably transformed cell is one in which the transforming polynucleotide has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming polynucleotide. A “clone” is a population of cells derived from a single cell or common ancestor by mitosis. A “cell line” is a clone of a primary cell that is capable of stable growth in vitro for many generations.
[0037] The term "vector” or “construct" refers to polynucleotide sequence elements arranged in a definite pattern of organization such that the expression of genes/gene products that are operably linked to these elements can be predictably controlled. Typically, they are transmissible polynucleotide sequences (e.g., plasmid or virus) into which a segment of foreign polynucleotide sequence can be spliced in order to introduce the foreign DNA into host cells to promote its replication and/or transcription. Vectors capable of directing the expression of heterologous polynucleotide or target gene sequences encoding for one or more polypeptides are referred to as "expression vectors" or "expression constructs".
III. Modified RNAs with stabilizing motifs
[0038] In one aspect, the invention provides modified or stabilized RNA molecules that can be expressed in specific tissue or cell types. A general strategy for obtaining such modified RNAs of the invention is shown in Figure 4. The modified RNAs contain an RNA of interest or “target RNA” (e.g., an mRNA encoding a therapeutic protein) and a sequence motif (or “stabilizing motif’ or “stabilizing element”) that is appended at the 5’ end of the RNA of interest. Typically, the RNA of interest is uncapped, non-canonically capped or decapped to allow attachment of the stabilizing motif. In some preferred embodiments, the target RNA of interest is an mRNA. Due to fusing of the stabilizing motif, the resulting target RNA (“modified target RNA molecule” or “modified RNA”) is able to bind via base pairing to a miRNA molecule (e.g., miR-122) that is specifically or abundantly expressed in one or more target tissue or cell types (e.g., liver cells).
[0039] In various embodiments, the target RNA of interest to be modified encodes a therapeutic polypeptide, an antibody or an antibody fragment. In some embodiments, the miRNA to which the stabilizing motif binds can regulate gene expressions that are associated with a cellular process or disease development, e.g., tumor development. In some of these embodiments, the sequence motif amended to the target RNA is complementary to a tissue-
or cell-specific miRNA. In some embodiments, the stabilizing motif is complementary to the seed region of the miRNA. In some of these embodiments, the stabilizing motif is further complementary to the supplementary region of the miRNA.
[0040] In some embodiments, a structured RNA element found near the 5' terminus of the RNA genome of Hepatitis C Virus (HCV) can be employed as the stabilizing motif in the invention. As exemplified herein, this sequence motif is able to base pair with miRNA-122, which is highly expressed in liver, associated with cholesterol metabolism and hepatocellular carcinoma, and plays an important role in HCV replication. HCV is a positive-strand RNA virus and human pathogen that can persist in liver cells for decades. Interactions between the HCV genomic RNA and the liver-specific miRNA miR-122 have been shown to be essential for maintaining HCV RNA abundance during viral infection (PMID: 16141076, 18621012, 19965718). Two sites complementary to miR-122 have been identified near the 5' terminus of the HCV RNA genome, and miR-122 binding has been proposed to mask the uncapped HCV RNA 5' terminus from attack by cellular exonucleases (PMID: 21220300, 23416544).
[0041] In some embodiments, the stabilizing motif in the modified RNA molecules of the invention contains a sequence that is substantially identical (e.g., at least 75%, 85%, 90%, 95% or 99% identical) to the first 29 nucleotides at the 5’ of human HCV genome, 5’- gcca gccg ccug augg cggc gaca cucca - 3’ (SEQ ID NO: 1). These modified RNAs are stabilized in liver cells via protective interactions with endogenous Ago-miR122 complexes. In some of these embodiments, nucleotides 1-4 (counting from the 5' end) of the stabilizing motif correspond to the reverse complement of nucleotides 14-17 of miR-122 (where nucleotide 1 of the modified target RNA is complementary to nucleotide 17 of the miRNA). In some of these embodiments, the modified target RNA further has its sequence immediately after nucleotide 4 encoding an RNA hairpin structure. For example, starting at residue 5, the modified target RNA can contain the sequence: gccgccugauggcggc (SEQ ID NO:2). In some embodiments, the modified target RNA has immediately following the hairpin sequence a single G nucleotide (corresponding to t9G). In some embodiments, the sequence after the G nucleotide in the modified target RNA should be the reverse complement of nucleotides 2-8 of the reference miRNA. In still some embodiments, the final nucleotide in the appended motif of the modified target RNA is an A residue (corresponding to tlA). In some embodiments, the stabilizing motif contains a sequence that is conservatively modified variant of SEQ ID NO: 1. In some other embodiments, the sequence of the stabilizing motif is identical to SEQ ID NO:1.
[0042] In some other embodiments, the stabilizing motif appended at the 5’ of a target RNA is modified from the 29-nt HCV 5’ sequence (SEQ ID NO:1). This modified stabilizing motif is made to be complementary to the target RNA pairing site of another tissue-specific miRNA (“reference miRNA”) other than miR-122. In some embodiments, sequence of the HCV derived stabilizing motif can be altered so that it is complementary to the seed and/or supplementary regions of other miRNAs. RNAs modified at the 5’ end with such altered stabilizing motifs are stabilized in cell types in which a given miRNA is specifically or highly expressed. In some embodiments, nucleotides 1^4 (counting from the 5' end) of the altered stabilizing motif RNA of interest are the reverse complement of the nucleotide sequence of 14-17 of the given miRNA (where nucleotide 1 of the altered stabilizing motif is complementary to nucleotide 17 of the miRNA). The sequence immediately after nucleotide 4 in the altered stabilizing motif encodes an RNA hairpin structure of about 16 nucleotides. The hairpin sequence can immediately be followed by a single G nucleotide (corresponding to t9G). The sequence after the G nucleotide should be the reverse complement of nucleotides 2-8 of the given miRNA. The final nucleotide in the altered stabilizing element appended to the RNA of interest can be an A (corresponding to tl A).
[0043] By appending to a target RNA of interest a stabilizing motif that is complementary to various miRNAs that are specifically or abundantly expressed in different tissue or cell types, the modified RNAs of interest are stabilized in the different target tissue or cell types. In general, each human cell type typically expresses one or two abundant miRNAs, which can be used as signatures for each cell type. Studies of miRNA expression patterns have shown that abundant miRNAs are often restricted to discrete human tissues. Notable miRNA families with high tissue specificity include, e.g., miR-378, miR-506, miR-8, miR-28, miR-15, miR-320, miR-10, miR181-, let-7, miR-17, miR-379, miR-29, miR-154, miR-30, miR-368, miR-188, miR-743, miR-34, miR-1273, miR-374, miR-130, miR-500, miR-515, miR-449, and 548. See, e.g., Lugwig et al., Nucleic Acids Res. 44(8):3865-77, 2016. By designing a stabilizing motif corresponding to a miRNA that is specifically or abundantly expressed in a given cell type, a target RNA can be stabilized and/or specifically expressed in many different types of tissues and cells.
[0044] In addition to miR-122 for expression in liver cell as exemplified herein, other examples of human miRNAs and corresponding tissue/cell specificities include, e.g., miR-9, miR-124 and miR 128a/b in brain; miR-7, miR-375, miR-141 and miR200a in pituitary gland; miR-142, miR-144, miR150, miR-155 and miR-223 in thyroid and hematopoietic cells
(vein and spleen); miR-l-3p, miR-133a-3p, miR-133b and miR-206 in myocardial tissues and muscle; miR205-5p in melanocytes, and miR-514a-3p and miR-192-5p in skin, testis and colon, respectively; miR-514a-3p in testis tissue; miR-449c-3p in spleen tissue; miR-449c-5p and miR-449b-5p in kidney and small intestine; miR-449a in lung, kidney and brain; and miR-449b-3p in spleen. Further description of tissue specificities of various human miRNAs can be found in, e.g., Lugwig et al., Nucleic Acids Res. 44(8):3865-77, 2016; Guo et al., Sci Rep 4, 5150, 2014; Panwar et al., Bioinformatics 33: 1554-60, 2017; McCall et al., Genome Res. 27: 1769-1781, 2017; Juzenas et al., Nucleic Acids Res. 45: 9290-9301, 2017; Pomper et al., Scientific Reports 10: 4921, 2020; Moreau et al., Arterioscler Thromb Vase Biol. 41 :2149-2167, 2021.
[0045] Appending a target RNA sequence with a 5’ stabilizing motif can be readily performed with standard techniques of molecular biology. As noted above, the target RNA sequence can be modified directly before being introduced into a specific cell type. Alternatively, fusing of the stabilizing motif to the target RNA sequence can be accomplished at the DNA level, i.e., by manipulating a DNA sequence that encodes the target RNA sequence. A modified DNA sequence that encodes the target RNA with an appended 5’ stabilizing motif can then be introduced into the desired tissue or cell type, typically via an expression construct, to promote expression of an encoded polypeptide of interest. The invention accordingly also provides expression constructs (RNA or DNA) that harbor or encode the modified RNAs described herein.
[0046] The expression constructs of the invention contain or encode a modified RNA described herein, and are suitable for introducing into a target tissue or cell. They are typically circular vectors and, in addition to the stabilizing motif bearing sequence (DNA or RNA) that encodes the polypeptide of interest, can also contain selectable markers, an origin of replication, and other elements. For example, the vector can contain a selection marker. The selection marker allows one to select for cells into which the vector has been introduced and/or stably integrated. In some embodiments, the selection marker can be a polynucleotide encoding a protein or enzyme that confers to the cells visually identifiable characteristics. For example, the vector can harbor a selection marker encoding Renilla luciferase reporter enzyme. Other examples include jellyfish green fluorescent protein (GFP) and bacterial β- galactosidase. In some other embodiments, the selection marker for identifying host cells into which the vector was introduced and/or stably integrated can be an antibiotic resistance gene. Examples of such markers include antibiotic resistance genes for neomycin, chloramphenicol,
blasticidin, hygromycin, and zeocin. The expression vectors of the invention can also bear other DNA sequences that may be necessary for proper RNA transcription and processing, as well as proper ribosome assembly and function. For example, some vectors of the invention additionally harbor sequences corresponding to the 5’-ETS and ITS elements of the precursor RNA sequence.
[0047] For controlling gene expression in mammalian cells, the expression constructs can be recombinantly produced with many vectors well known in the art. These include viral vectors such as recombinant adenovirus, retrovirus, lentivirus, herpesvirus, poxvirus, papilloma virus, or adeno-associated virus. The vectors can be present in liposomes, e.g., neutral or cationic liposomes, such as DOSPA/DOPE, DOGS/DOPE or DMRIE/DOPE liposomes, and/or associated with other molecules such as DNA-anti-DNA antibody-cationic lipid (DOTMA/DOPE) complexes. Exemplary viral vectors suitable for the invention are described herein. For in vivo application, the expression vectors may be administered to a subject via any route including, but not limited to, intramuscular, buccal, rectal, intravenous or intracoronary routes.
[0048] Expression constructs containing or encoding a modified RNA described herein can be readily constructed in accordance with methodologies known in the art of molecular biology in view of the exemplifications provided herein specification. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (3rd ed., 2001); Brent et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (ringbou ed., 2003); and Freshney, Culture of Animal Cells: A Manual of Basic Technique, Wiley -Liss, Inc. (4th ed., 2000).
IV. Target proteins encoded by modified RNAs containing stabilizing motif [0049] In general, the target RNA molecule (or RNA of interest) stabilized with methods of the invention can encode any exogenous proteins or polypeptides that are desired for the specific cell type. In some embodiments, the target RNA molecule encodes a therapeutic polypeptide. These methods can be employed in therapeutic applications for delivering and expressing the stabilizing motif-appended RNA molecules in human tissues and cells that have abundant expression of a corresponding miRNA complementary to the stabilizing motif. By expressing an exogenous therapeutic polypeptide, the methods of the invention can be used in the prevention and/or cure of many important human diseases, including many diseases which are not amenable to treatment by other therapies. For a review of therapeutic
gene transfer procedures, see, e.g., Anderson, Science 256:808-813, 1992; Nabel & Feigner, TIBTECH 11 :211-217, 1993; Mitani & Caskey, TIBTECH 11 :162-166, 1993; Mulligan, Science 926-932, 1993; Dillon, TIBTECH 11 : 167-175, 1993; Miller, Nature 357:455-460, 1992; Van Brunt, Biotechnology 6: 1149-1154, 1998; Vigne, Restorative Neurology and Neuroscience 8:35-36, 1995; Kremer & Perricaudet, British Medical Bulletin 51 :31-44, 1995; Haddada et al., in Current Topics in Microbiology and Immunology (Doerfler & Bohm eds., 1995); and Yu et al., Gene Therapy 1 :13-26, 1994.
[0050] In various embodiments, a stabilized mRNA molecule of the invention can be transferred, for example to treat cancer cells, to express immunomodulatory genes to fight viral infections, or to replace a gene’s function as a result of a genetic defect. The exogenous mRNA (or corresponding DNA sequence) can also encode an antigen of interest for the production of antibodies. In some exemplary embodiments, the exogenous sequence to be transferred with the methods of the present invention is a polynucleotide that encodes an enzyme. For example, the gene can encode a cyclin-dependent kinase (CDK). It was shown that restoration of the function of a wild-type cyclin-dependent kinase, pl6INK4, by transfection with a p 16INK4-expressing vector reduced colony formation by some human cancer cell lines (Okamoto, Proc. Natl. Acad. Sci. U.S.A. 91 :11045-9, 1994). Additional embodiments of the invention encompass transferring into target cells exogenous genes that encode cell adhesion molecules or therapeutic antibodies, other tumor suppressors such as p21 and BRCA2, inducers of apoptosis such as Bax and Bak, other enzymes such as cytosine deaminases and thymidine kinases, hormones such as growth hormone and insulin, and interleukins and cytokines.
[0051] Some stabilized RNA molecules of the invention can encode an antibody or antibody fragment. These include many known antibody-related molecules that are well characterized in the art, e.g., CD4-Ig, eCD4-Ig, PG9, PG16, PGT121, PGT128, 10-1074, PGT145, PGT151, CAP256, 2F5, 4E10, 10E8, 3BNC117, VRC01, VRC07, VRC13, PGDM1400, PGV04, 2G12, bl2, N6, TR66, etanercept, abatacept, rilonacept, aflibercept, belatacept, romiplostim, efmoroctocog, eftrenonacog, asfotase alpha, muromonab-CD3, edrecolomab, capromab, ibritumomab, blinatumomab, abciximab, rituximab, basiliximab, infliximab, cetuximab, brentuximab, siltuximab, palivizumab, trastuzumab, alemtuzumab, omalizumab, bevacizumab, natalizumab, ranibizumab, eculizumab, certolizumab, pertuzumab, obinutuzumab, pembrolizumab, vedolizumab, elotuzumab, idarucizumab, mepolizumab, adalimumab, panitumumab, canakinumab, golimumab, ofatumumab,
ustekinumab, denosumab, belimumab, ipilimumab, raxibacumab, nivolumab, ramucirumab, alirocumab, daratumumab, evolocumab, necitumumab, and secukinumab. In some other embodiments, the transgene in the expression vectors of the invention can encode at least a chain or functional fragment derived from any of the other known cellular proteins such as cellular receptors, other cell surface molecules, enzymes, cytokines, chemokines, costimulatory molecules, interleukins, and physiologically active polypeptide factors. Examples of these known cellular proteins include, e.g., CD4, TPST1, TPST2, TNFR II, CD28, CTLA-4, PD-1, PD-L1, PD-L2, 4-1BBL, 4-1BB, EPO, Factor VIII, Factor IX, alkaline phosphatase, hemoglobin, fetal hemoglobin, and RPE65. In some of these embodiments, the polypeptide expressed from the rAAV vectors of the invention is at least part of a chimeric antigen receptor (CAR).
[0052] Some stabilized RNA molecules of the invention can encode one or more other therapeutic polypeptide agents that are well-known known in the art. These include factor VIII, factor IX, β-globin, low-density lipoprotein receptor, adenosine deaminase, purine nucleoside phosphorylase, sphingomyelinase, glucocerebrosidase, cystic fibrosis transmembrane conductance regulator, a-antitrypsin, CD-18, ornithine transcarbamylase, argininosuccinate synthetase, phenylalanine hydroxylase, branched-chain a-ketoacid dehydrogenase, fumarylacetoacetate hydrolase, glucose 6-phosphatase, a-L-fucosidase, β- glucuronidase, a-L-iduronidase, galactose 1 -phosphate uridyltransferase, interleukins, cytokines, small peptides, and the like. Other therapeutic proteins that can be expressed from a transgene in the engineered viral vectors of the invention include, e.g., Herceptin®, polypeptide antigens from various pathogens such as disease causing bacteria or viruses (e.g., E. coli, P. aeruginosa, S. aureus, malaria, HIV, rabies virus, HBV, and cytomegalovirus), and other proteins such as lactoferrin, thioredoxin and beta-casein.
[0053] Additional examples of therapeutic agents or proteins of interest include, but are not limited to, insulin, erythropoietin, tissue plasminogen activator (tPA), urokinase, streptokinase, neutropoiesis stimulating protein (also known as filgastim or granulocyte colony stimulating factor (G-CSF)), thrombopoietin (TPO), growth hormone, emoglobin, insulinotropin, imiglucerase, sarbramostim, endothelian, soluble CD4, and antibodies and/or antigen-binding fragments (e g., FAbs) thereof (e g., orthoclone OKT-e (anti-CD3), GPIIb/IIa monoclonal antibody), ciliary neurite transforming factor (CNTF), granulocyte macrophage colony stimulating factor (GM-CSF), brain-derived neurite factor (BDNF), parathyroid hormone(PTH)-like hormone, insulinotrophic hormone, insulin-like growth factor- 1 (IGF-1),
platelet-derived growth factor (PDGF), epidermal growth factor (EGF), acidic fibroblast growth factor, basic fibroblast growth factor, transforming growth factor 0, neurite growth factor (NGF), interferons (IFN) (e.g., IFN-α2b, IFN-α2a, IFN-αN1, IFN-plb, IFN-y), interleukins (e.g., IL-1, IL-2, IL-8), tumor necrosis factor (TNF) (e.g., TNF-α, TNF-0), transforming growth factor-α and -0, catalase, calcitonin, arginase, phenylalanine ammonia lyase, L-asparaginase, pepsin, uricase, trypsin, chymotrypsin, elastase, carboxypeptidase, lactase, sucrase, intrinsic factor, vasoactive intestinal peptide (VIP), calcitonin, Ob gene product, cholecystokinin (CCK), serotonin, and glucagon.
V. Stabilizing and promoting expression of target RNAs in specific tissues or cells [0054] In one aspect, the invention provides methods of stabilizing or enhancing stability of an RNA molecule in selected tissue or cell types. The methods utilize modified RNAs that contain an appended stabilizing motif as described above. By including corresponding complementary sequence motifs (e.g., motifs complementary to seed and/or supplementary duplexes of a miRNA), the stabilizing motif can enable the target RNA to bind to a miRNA molecule specifically or predominantly expressed in one or several specific tissue or cell types. Binding by the miRNA to the modified target RNA molecule protects it from degradation by cellular exonucleases (primarily XRN-1 and XRN-2), thereby stabilizing the target RNAs in the specific tissue- or cell- types. In contrast, RNAs lacking a canonical 5' cap structure are subject to degradation by the cellular exonucleases. Thus, cells or tissues lacking the specified miRNA will be unable to accumulate the target RNA of interest. These methods of the invention can be employed to stabilize a target RNA in tissue or cell types that specifically or abundantly express any of the tissue- or cell- specific miRNAs known in the art.
[0055] In a related aspect, the invention also provides methods of promoting or enhancing expression of a target RNA (e g , an mRNA) in a specific or specified cell type. In these methods, the target RNA is modified by fusing or appending at its 5’ a stabilizing motif that specifically binds to a miRNA. The target RNA molecule thus modified (or its encoding DNA sequence) is introduced into a specific cell type (e g., liver cell) in which the corresponding miRNA (e.g., miR-122) is differentially or abundantly expressed. By stabilizing a protein encoding RNA molecule or enhancing its stability in the desired tissue or cell types, selective expression of the protein encoded by the target RNA molecule (e.g., a therapeutic protein) can be achieved.
[0056] To practice methods of the invention, the stabilizing element may be appended to the 5' end of any uncapped or non-canonically capped RNA for which accumulation in specific cell types is desired. If placed upstream of an appropriate Internal Ribosomal Entry Site (IRES), the stabilizing element may enable exogenous mRNAs to be expressed in specified cell types (e g., cancer cells, cardiac cells, neurons, etc.). The methods for expressing an exogenous mRNA appended with a stabilizing motif in a specific cell that expressing a corresponding miRNA are exemplified in the experimental data described in Example 4 below. In the practice of these methods of the invention, a stabilizing motif bearing RNA of interest can be directly introduced into a corresponding specific cell type via standard techniques of molecule biology. In some other embodiments, delivering a modified exogenous RNA sequence into the specific cell type is achieved by first generating a DNA sequence encoding the stabilized RNA and then introducing the DNA sequence (e.g., via suitable expression vector) into the desired specific cell type.
[0057] The modified RNA molecules of the invention or DNA sequences encoding the same (e g., an expression vector) can be delivered to specific tissues or cells with various methods well known in the art. In some embodiments, a transfection agent is used. A transfection agent, or transfection reagent or delivery vehicle, is a compound that binds to or complexes with oligonucleotides and polynucleotides, and enhances their entry into cells. Examples of transfection reagents include, but are not limited to, cationic liposomes and lipids, polyamines, calcium phosphate precipitates, polycations, histone proteins, polyethylenimine, polylysine, and polyampholyte complexes. Transfection reagents are well known in the art. Examples of transfection reagents suitable for delivery of mRNA molecules include Magic™ mRNA Transfection Reagent (Creative Biolabs) and in vivo-jetRNA® (Polyplus).
[0058] Reagents for delivery of modified target RNA molecules of the invention or their encoding DNA sequences into specific tissue or cells include, but are not limited to protein and polymer complexes (polyplexes), lipids and liposomes (lipoplexes), combinations of polymers and lipids (lipopolyplexes), and multilayered and recharged particles. Transfection agents may also condense nucleic acids. Transfection agents may also be used to associate functional groups with a polynucleotide. Functional groups can include cell targeting moieties, cell receptor ligands, nuclear localization signals, compounds that enhance release of contents from endosomes or other intracellular vesicles (such as membrane active compounds), and other compounds that alter the behavior or interactions of the compound or
complex to which they are attached (interaction modifiers). For delivery in vivo, complexes made with sub-neutralizing amounts of cationic transfection agent may be preferred.
[0059] In some embodiments, polycations are mixed with polynucleotides for delivery to a cell. Poly cations are a very convenient linker for attaching specific receptors to DNA and as result, DNA/polycation complexes can be targeted to specific cell types. An endocytic step in the intracellular uptake of DNA/polycation complexes is suggested by results in which functional DNA delivery is increased by incorporating endosome disruptive capability into the polycation transfection vehicle. Polycations also cause DNA condensation. The volume which one DNA molecule occupies in complex with polycations is drastically lower than the volume of a free DNA molecule. The size of DNA/polymer complex may be important for gene delivery in vivo.
[0060] Polymer reagents for delivery of a nucleic acid molecule may incorporate compounds that increase their utility. These groups can be incorporated into monomers prior to polymer formation or attached to polymers after their formation. An anti-miRNA transfer enhancing moiety is typically a molecule that modifies a nucleic acid complex and can direct it to a cell location (such as tissue cells) or location in a cell (such as the nucleus) either in culture or in a whole organism. By modifying the cellular or tissue location of the complex, the desired localization and activity of the polynucleotide can be enhanced. The transfer enhancing moiety can be, for example, a protein, peptide, lipid, steroid, sugar, carbohydrate, nucleic acid, cell receptor ligand, or synthetic compound. The transfer enhancing moi eties can enhance cellular binding to receptors, cytoplasmic transport to the nucleus and nuclear entry or release from endosomes or other intracellular vesicles.
[0061] Nuclear localizing signals can also be used to enhance the targeting of the nucleic acid molecule into proximity of the nucleus and/or its entry into the nucleus. Such nuclear transport signals can be a protein or a peptide such as the SV40 large Tag NLS or the nucleoplasmin NLS. These nuclear localizing signals interact with a variety of nuclear transport factors such as the NLS receptor (karyopherin alpha) which then interacts with karyopherin beta. The nuclear transport proteins themselves could also function as NLS's since they are targeted to the nuclear pore and nucleus.
[0062] Compounds that enhance release from intracellular compartments can cause DNA release from intracellular compartments such as endosomes (early and late), lysosomes, phagosomes, vesicle, endoplasmic reticulum, Golgi apparatus, trans Golgi network (TGN), and sarcoplasmic reticulum and could be used to aid delivery of the anti-miRNA molecule.
Release includes movement out of an intracellular compartment into cytoplasm or into an organelle such as the nucleus. Such compounds include chemicals such as chloroquine, bafilomycin or Brefeldin Al and the ER-retaining signal (KDEL sequence), viral components such as influenza virus hemagglutinin subunit HA-2 peptides and other types of amphipathic peptides.
[0063] Cellular receptor moieties are any signal that enhances the association of the nucleic acid molecule with a cell. Enhanced cellular association can be accomplished by either increasing the binding of the polynucleotide or polynucleotide complex to the cell surface and/or its association with an intracellular compartment, for example: ligands that enhance endocytosis by enhancing binding the cell surface. Cellular receptor moieties include agents that target to asialoglycoprotein receptors by using asialoglycoproteins or galactose residues. Other proteins such as insulin, EGF, or transferrin can be used for targeting. Peptides that include the RGD sequence can also be used to target many cells. Chemical groups that react with sulfhydryl or disulfide groups on cells can also be used to target many types of cells. Folate and other vitamins can also be used for targeting. Other targeting groups include molecules that interact with membranes such as lipids fatty acids, cholesterol, dansyl compounds, and amphotericin derivatives. In addition, viral proteins could be used to target cells.
[0064] The invention further provides engineered mammalian cells which express a modified RNA sequence described herein. Various mammalian cells can be employed for introducing an expression construct of the invention or by stably integrating the rDNA described herein into the host genome. Polynucleotides containing or encoding the modified RNA can be introduced into an appropriate host cell (e.g., a mammalian cell such as 293T cell, N2a cell or CHO cell, or PBMC, or primary immune cells) by any means known in the art. The cells can transiently or stably express the introduced vectors containing or encoding the target RNA. Preferably, mammalian cells are used in these embodiments of the invention. Mammalian expression systems allow for proper post-translational modifications of expressed mammalian proteins to occur, e.g., proper processing of the primary transcript, glycosylation, phosphorylation and advantageously secretion of expressed product. Suitable cells include cells rodent, cow, goat, rabbit, sheep, non-human primate, human, and the like). Specific examples of cell lines include CHO, BHK, HEK293, N2a, VERO, HeLa, COS, MDCK, and W138. Any convenient protocol may be employed for in vitro or in vivo introduction of the expression vector into the host cell, depending on the location of the host
cell. In some embodiments, where the host cell is an isolated cell, the expression construct may be introduced directly into the cell under cell culture conditions permissive of viability of the host cell, e.g., by using standard transformation techniques.
EXAMPLES
[0065] The following examples are offered to illustrate, but not to limit the present invention.
Example 1. Atomic details of the Ago2-miR122-HCV interaction activity
[0066] Taking into consideration that miRNAs function in complex with Argonaute proteins, we determined the 3.0 A resolution crystal structure of human Argonaute2 (Ago2) bound to miR-122 and an RNA oligonucleotide corresponding to the first 29 nucleotides of the 5' terminus of the HCV genome (PMID: 34824224). This nucleotide sequence represents the miR-122 complementary site residing at the very 5' end of the HCV genome (Figure 1).
[0067] The crystal structure shows base-pairing interactions between the HCV RNA and miR-122. Specifically, nucleotides 2-8 and 14-17 of miR-122 (counting from the 5' end of miR-122) pair with the HCV RNA, forming two RNA duplex regions termed ‘seed duplex’ and ‘supplementary duplex’, respectively (Figure 1). Seed and supplementary duplexes are separated by a stem -loop structure (SL1) in the HCV RNA, thereby forming a three-way RNA junction.
[0068] The crystal structure also shows contacts between Ago2 and the HCV RNA. SL1 of the HCV RNA inserts between the Ago2 PIWI and PAZ domains, locking Ago2 in an opened conformation. HCV nucleotide G21 (corresponding to the ‘t9’ position in miRNA- targeting nomenclature) inserts into a surface pocket in the Ago2 PIWI domain, termed the t9G-binding pocket. HCV nucleotide A29 inserts into a binding pocket in the Ago2 MID domain termed the tlA-binding pocket (PMID: 26359634).
Example 2. Defined contacts to Ago2-miR122 stabilize the HCV RNA
[0069] In vitro biochemical experiments show the Ago2-miR122 complex dramatically stabilizes RNA corresponding to the HCV 5' untranslated region (5'UTR, nucleotides 1-357 of the HCV genome) in the presence of the exonuclease XRN-1 (Figure 2, A). Stability depends on interactions between Ago2-miR122 and the miR-122 complementary site nearest to the 5' end of the HCV genome. Stability is compromised in HCV RNA mutants in which
base pairing in the seed duplex, supplementary (sup) duplex, or SL1 is disrupted (Figure 2,B). Similarly, cell-based assays show that base pairing in the seed duplex and SL1 is necessary for maintaining HCV RNA levels after transfection into the human cell line Huh-7.5.1 (Figure 2,C). The combined structural and functional data reveal contacts to the Ago2- miR122 complex that dramatically stabilize the HCV RNA in the presence of 5'-3' exonucleases.
Example 3. Human miRNAs display discrete and diverse expression patterns [0070] Studies of miRNA expression patterns have shown that abundant miRNAs are often restricted to discrete human tissues (PMID: 26921406). Tumors and cancer cells also often display unique miRNA expression patterns. Thus, in many cases, expression of a particular miRNA may be used as a molecular signature for a specific cell type (Figure 3).
Example 4. Expressing stabilized exogenous mRNAs in specific cell types [0071] This example describes expression of exogenous mRNAs appended with a stabilizing motif in a specific cell type in the presence of corresponding miRNAs. [0072] We first tested expression of modified mRNAs in HEK293 cells with exogeneously introduced miRNAs that are recognized by the 5’ stabilizing motif in the modified mRNAs. Specifically, uncapped mRNAs, encoding a luciferase reporter gene, were produced with stabilizing elements specific to either miRNA-A or miRNA-B (two artificial miRNAs, not naturally present in HEK293 cells). mRNAs were transfected into HEK293 cells with miRNA-A, or miRNA-B, or no exogenous miRNA. Expression levels of the luciferase reporter were subsequently measured in each sample (Figure 5, A). The results indicate that co-transfection of the mRNA containing a stabilizing element recognized by miRNA-A with miRNA-A led to approximately 10 times more luciferase activity than transfection of the same mRNA without a miRNA or with miRNA-B, demonstrating upregulation dependent on recognition by miRNA-A ((Figure 5, B, right). Similarly, the presence of miRNA-B promoted the expression of the mRNA containing a stabilizing element specifically recognized by miRNA-B (Figure 5, B, left). These results indicate that the miRNA-specific stabilizing effects observed in vitro are recapitulated in living cells.
[0073] We also examined expression of modified mRNAs in the presence of endogenously expressed miRNAs. Huh-7 cells, which naturally express the miRNA miR- 122, were transfected with a reporter mRNA that contained a stabilizing element specifically
recognized by miR-122. Transfection of Huh-7 cells with a reporter mRNA lacking complementarity to miR-122 was used as a negative control. As shown in Figure 6, the mRNA containing the miR-122-specific stabilizing element produced approximately 6 times more luciferase activity than the negative control. These results indicate that endogenous miRNAs can be leveraged for preferential stability /expression enhancement of RNAs containing cognate-stabilizing elements.
[0074] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
[0075] All publications, databases, GenBank sequences, patents, and patent applications cited in this specification are herein incorporated by reference as if each was specifically and individually indicated to be incorporated by reference.
Claims
1. A modified RNA molecule, comprising (a) a target RNA sequence and (b) a stabilizing motif at the 5’ of the target RNA sequence, wherein the stabilizing motif is capable of binding to a miRNA sequence that is specifically or predominantly expressed in one or several specific tissue or cell types.
2. The modified RNA molecule of claim 1, which the target RNA sequence is an mRNA.
3. The modified RNA molecule of claim 1, wherein the stabilizing motif is complementary to the seed region of the miRNA.
4. The modified RNA molecule of claim 3, wherein the stabilizing motif is further complementary to the supplementary region of the miRNA.
5. The modified RNA molecule of claim 1, wherein the stabilizing motif comprises a sequence that is substantially identical to the first 29 nucleotides at the 5’ of human HCV genome (SEQ ID NO: 1).
6. The modified RNA molecule of claim 1, wherein the stabilizing motif comprises from 5’ to 3’ (a) nucleotides 1-4 that are complementary to nucleotides 17-14 of the miRNA, wherein nucleotide 1 of the stabilizing motif is complementary to nucleotide 17 of the miRNA, (b) a hairpin of about 16 nucleotides, (c) a G nucleotide, (d) a sequence of about 7 nucleotides that are complementary to nucleotides 8-2 of the miRNA, and (e) an A nucleotide.
7. The modified RNA molecule of claim 6, wherein the hairpin comprises the sequence 5’- gccgccugauggcggc - 3’ (SEQ ID NO:2).
8. The modified RNA molecule of claim 1, wherein the target RNA sequence encodes a therapeutic polypeptide, an antibody or an antibody fragment.
9. A method for stabilizing a target RNA molecule in a specific tissue or cell, comprising (a) appending or fusing at the 5’ end of the target RNA molecule a stabilizing
motif to generate a modified target RNA molecule, wherein the stabilizing motif is able to bind via base paring to a miRNA that is specifically or abundantly expressed in the specific tissue or cell; and (b) introducing into the cell the modified target RNA molecule or a DNA molecule encoding the modified target RNA molecule; thereby stabilizing the target RNA molecule in the specific tissue or cell.
10. The method of claim 9, wherein the target RNA molecule is uncapped or non-canonically capped prior to appending the stabilizing motif.
11. The method of claim 9, wherein the target RNA molecule is an mRNA molecule.
12. The method of claim 9, wherein the stabilizing motif is complementary to the seed region of the miRNA.
13. The method of claim 12, wherein the stabilizing motif is further complementary to the supplementary region of the miRNA.
14. The method of claim 9, wherein the stabilizing motif comprises a sequence that is substantially identical to the first 29 nucleotides at the 5’ of human HCV genome (SEQ ID NO:1), and the specific cell is a liver cell.
15. The method of claim 14, wherein the stabilizing motif comprises from 5’ to 3’ (a) nucleotides 1-4 that are complementary to nucleotides 17-14 of the miRNA, wherein nucleotide 1 of the target RNA is complementary to nucleotide 17 of the miRNA, (b) a hairpin of about 16 nucleotides, (c) a G nucleotide, (d) a sequence of about 7 nucleotides that are complementary to nucleotides 8-2 of the miRNA, and (e) an A nucleotide.
16. The method of claim 15, wherein the hairpin comprises the sequence 5’- gccgccugauggcggc - 3’ (SEQ ID NO:2).
17. The method of claim 9, wherein the specific tissue or cell is a cancer cell, a cardiac cell or a neuron.
18. The method of claim 9, wherein the target RNA molecule encodes a therapeutic polypeptide, an antibody or an antibody fragment.
19. The method of claim 9, wherein the specific tissue or cell is brain, and the miRNA is miR-9, miR-124 or miR-128a/b.
20. The method of claim 9, wherein the specific tissue or cell is pituitary gland, and the miRNA is miR-7, miR-375, miR-141 or miR200a.
21. The method of claim 9, wherein the specific tissue or cell is thyroid or hematopoietic cell, and the miRNA is miR-142, miR-144, miR150, miR-155 or miR-223.
22. The method of claim 9, wherein the specific tissue or cell is myocardial or muscle, and the miRNA is miR-l-3p, miR-133a-3p, miR-133b or miR-206.
23. The method of claim 9, wherein the specific tissue or cell is melanocyte, and the miRNA is miR205-5p.
24. The method of claim 9, wherein the specific tissue or cell is skin, testis and colon, and the miRNA is respectively miR-205-5p, miR-514a-3p and miR-192-5p.
25. The method of claim 9, wherein the specific tissue or cell is spleen tissue, and the miRNA is miR-449c-3p or miR-449b-3p.
26. The method of claim 9, wherein the specific tissue or cell is testis tissue, and the miRNA is miR-514a-3p.
27. The method of claim 9, wherein the specific tissue or cell is kidney or small intestine, and the miRNA is miR-449c-5p or miR-449b-5p.
28. The method of claim 9, wherein the specific tissue or cell is lung, kidney and brain, and the miRNA is miR-449a.
29. A method for expressing a target RNA molecule in a specific tissue or cell, comprising (a) appending at the 5’ of the target RNA molecule a stabilizing motif to generate a modified target RNA molecule, wherein the stabilizing motif is complementary to a miRNA that is specifically or abundantly expressed in the specific tissue or cell; and (b) introducing the modified target RNA molecule or a DNA sequence encoding the modified
target RNA into the specific cell type; thereby expressing the target RNA molecule in the specific tissue or cell.
30. The method of claim 29, wherein the target RNA molecule is exogenous to the specific tissue or cell.
31. The method of claim 29, wherein the specific tissue or cell is present in a human subject.
32. The method of claim 29, wherein the specific tissue or cell is a cancer cell, a cardiac cell or a neuron.
33. The method of claim 29, wherein the target RNA molecule encodes a therapeutic polypeptide, an antibody or an antibody fragment.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263392393P | 2022-07-26 | 2022-07-26 | |
US63/392,393 | 2022-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024023580A2 true WO2024023580A2 (en) | 2024-02-01 |
Family
ID=89705578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/000449 WO2024023580A2 (en) | 2022-07-26 | 2023-07-25 | Stabilizing rnas with mirna-binding motifs |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024023580A2 (en) |
-
2023
- 2023-07-25 WO PCT/IB2023/000449 patent/WO2024023580A2/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5735927B2 (en) | Re-engineering the primary structure of mRNA to enhance protein production | |
CN113939591A (en) | Methods and compositions for editing RNA | |
US20220112489A1 (en) | Trem compositions and uses thereof | |
JP2021529518A (en) | Compositions and Methods for Genome Editing by Insertion of Donor polynucleotide | |
US7972816B2 (en) | Efficient process for producing dumbbell DNA | |
JP6445516B2 (en) | Production of recombinant polypeptides | |
WO2018089437A1 (en) | Compositions and methods for scarless genome editing | |
US20230272416A1 (en) | Method and system for delivering nucleic acid | |
WO2021076563A1 (en) | Efficient rna switches and related expression systems | |
WO2024023580A2 (en) | Stabilizing rnas with mirna-binding motifs | |
JP2012517230A (en) | Selection system based on RNAi | |
JP6676526B2 (en) | Means and methods for the production of mammalian production cells for the production of recombinant proteins | |
CN114026241A (en) | Stable targeted integration | |
JP2023507181A (en) | Nucleic acid constructs for delivering polynucleotides to exosomes | |
CN114829588A (en) | Methods and constructs for transient production of lentiviral vectors | |
US10556019B2 (en) | Human microRNAs for treatment of malignant tumours | |
WO2023074873A1 (en) | Cell purification method | |
CN110312801B (en) | Systems and methods for cell type specific translation of RNA molecules in eukaryotic cells | |
WO2023223219A1 (en) | IMPROVED PROTEIN PRODUCTION USING miRNA TECHNOLOGY | |
JP2015180203A (en) | REENGINEERING mRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION | |
CN117721151A (en) | CRISPR-dcas13d-eIF 4G-based protein translation activation system and application thereof | |
US20190256830A1 (en) | Method for cell-specifically controlling nuclease | |
Solanki | microRNAs as potential tools for ‘miR’aculous CHO cell phenotypes in Bioprocessing systems | |
McLachlan | Development of combinatorial RNAi transgenes targeting influenza virus | |
Feřtek | Side-effects of siRNA-induced gene silencing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23845766 Country of ref document: EP Kind code of ref document: A2 |